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ABSTRACT 
The thesis entitled "Quantitative analysis of certain antiadrenergic 
agents and angiotensin converting enzyme inhibitors in pharmaceutical 
formulations" is comprised of five chapters. The first chapter describes a 
general introduction of the subject matter which includes: 
• a detailed description of drug development process, manufacturing 
and control testing of drug as well as stability testing of active 
pharmaceutical ingredients and products. 
• various types of analytical techniques and procedures involving 
sophisticated instruments which are frequently used in the field under 
discussion. 
• analytical method can only be used for routine analysis when it fulfills 
certain performance criteria. Once the analytical method is advent, it is 
necessary to decide its suitability for the intended purpose. This is known as 
method validation. Several international organizations and regulatory 
authorities, which are involved in fixing the criteria for the validation are 
International Union of Pure and Applied Chemistry, International Laboratory 
Accreditation Conference, Western European Laboratory Accreditation 
Cooperation, International Conference on Harmonization and International 
Organization for Standardization. The most important validation parameters 
are accuracy, precision, selectivity, specificity, limits of detection and 
quantitation, robustness and ruggedness. When deciding for the validation of 
the method, the role of statistical analysis cannot be ignored. It is the only 
way to get the most conclusive results from the mathematical data during the 
spectrophotometric method based on the reduction of Fe(lll) with captopril. 
The reduced Fe(ll) reacts with potassium ferricyanide resulting in the 
formation of blue product. The reaction is followed spectrophotometrically by 
measuring the rate of change of absorbance at 730 nm. The initial rate is 
utilized for constructing the calibration graph, which was found to be linear in 
the range 1-11 pgmL'V The regression analysis of calibration data yielded 
the regression equation: 
log rate = 4.248 + 1.173 log c 
The stoichiometry of the reaction product was established from the Bent and 
French plots and the reaction proceeds in the molar ratio of 1:1:1. The 
sequence is shown as: 
S t e p I 
C ap to p rll 
^ / / H 3 C ' ' ' H. V_j 2 Fc " + 2 H 
S t e p II 
Fe^*+ [ Fe (C N )(, l ' + K*+ H jO F e " ' K ( F e " ( C N ) 6 l x H ^O 
The small value of variance of calibration line (2.38x10"^) and low value of 
detection linfiit (0.04 MS^L'^ ) pointed towards good sensitivity of the proposed 
procedure. The proposed procedure has been successfully applied to the 
deternnination of captopril in pharmaceutical preparations. The data obtained 
for the analysis of commercial dosage forms show that the true bias is less 
than ± 2.0%. 
In chapter three, two simple, rapid and sensitive spectrophotometric 
methods have been proposed for the determination of lisinopril in pure form 
and pharmaceutical formulations. The methods are based on the charge 
transfer complexation reaction of the drug with 7,7,8,8-
tetracyanoquinodimethane (TCNQ) and p-chloranilic acid (pCA) in polar 
media. The lisinopril-TCNQ and lisinopril-pCA charge transfer complexes 
dissociate in acetone and methanol, respectively and yield coloured TCNQ 
and pCA radical anions, which are measured spectrophotometrically at 743 
and 525 nm respectively. The Beer's law is obeyed in the concentration 
ranges of 2-26 and 25-300 jagmL"^  with molar absorptivity of 1.432x10'* and 
1.192x10'* Lmor^cm'^  for TCNQ and pCA methods, respectively. Both the 
methods have been applied to the determination of lisinopril in 
pharmaceutical dosage forms. The experimental true bias of all samples is 
less than ±2%. 
The fourth chapter describes a simple and sensitive kinetic 
spectrophotometric method for the determination of labetalol hydrochloride. 
The method is based on the kinetic investigation of the oxidation of the drug 
with alkaline potassium permanganate at room temperature. The increase in 
absorbance of coloured manganate ions was measured at 605 nm. The 
Initial rate and fixed time (at 6 min.) methods are adopted for determining the 
drug concentration. Under pseudo first order reaction condition, the rate 
equation can be written as: 
log rate = 2.147+ 0.902 log [labetalol] 
The calibration graphs are linear in the concentration ranges of 2 - 14 
jagmL"^  and 1 - 1 0 pgmL"^  using the initial rate and fixed time methods, 
respectively. The method has been successively applied to the 
determination of labetalol in laboratory made tablets. The results obtained for 
initial-rate and fixed time methods showed that the mean recoveries and 
relative standard deviations were in the range 99.49 - 100.87% and 0.52 -
1.35%, respectively. The calculated t and F values are less than the 
theoretical ones at 95% confidence level confirming that there is no 
significant difference in the performance of the proposed method and 
reference method with regard to accuracy and precision. 
The last chapter includes a simple and sensitive kinetic 
spectrophotometric method for the determination of perindopril in 
pharmaceutical preparations. The method is based on the interaction of drug 
with 1-chloro-2,4-dinitrobenzene in dimethylsulphoxide at 40±1°C. The 
reaction is followed spectrophotometrically by measuring the rate of change 
of the absorbance at 420 nm. Under the optimized experimental conditions, 
the calibration curve showed a linear relationship over the concentration 
range of 20-140 pgmL"^  The activation parameters such as Eg, AH*, AS* and 
AG* for this reaction were calculated and found to be 27.31 KJmor\ 24.69 
KJmor\ -138.84JK'''mor'' and 61.50 KJmol"^  respectively. The method has 
been successfully applied to the determination of perindopril in commercial 
dosage forms. The results of proposed method was compared with those of 
Abdellatefs spectrophotometric method, which confirmed that the limit of 
acceptance interval is within Qi = 0.98 and 9u = 1.02. 
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Chapter - 1 
General Introduction 
m i 
The development of a pharmaceutical product requires a broad spectrum of 
scientific expertise to lead it through the complex pathway from discovery through 
characterization of quality, efficacy and safety, which are the hallmarks of a 
successful drug product. A company must be highly proactive in setting targets for 
appraising and selecting a compound that has the highest probability of success. In 
addition, the compound and its therapeutic use must be consistent with the research 
and marketing goals of the company in order to leverage existing resources and 
experience. To ensure scientific and commercial success, it is critical to understand 
the drug development process (Fig. 1.1) and the myriad tasks and milestones that are 
vital to a comprehensive development plan. 
The ability to assure the physical and chemical properties of an active 
phannaceutical ingredient, drug product or nutraceutical is critical for regulator>' 
approval and therapeutic success. The effective chemistry, manufacturing and 
controls process is necessary for an efficient and comprehensive development 
strategy. The major challenges for the manufacturing and control component of drug 
development is to assure the chemical and physical properties of the compound and 
product are monitored at all critical phases of the pathway. This process matches the 
scientific and analytical tasks to the manufacturing and commercialization strategy 
(Table 1.1). 
In recent years, the International Conference on Harmonisation of technical 
requirements for registration of pharmaceuticals for human use (ICH) has adopted 
scientific standards for quality control monitoring [1]. These standards are the basis 
of most regulatory guidelines, including those published by the Food and Drug 
Administration [2]. Key steps on the path include pharmaceutical analysis and 
stability studies that are required to determine and assure the identity, potency and 

Table 1.1: Major Challenges for Manufacturing and Control 
> Maintain inventory for development and marketing 
> Physical and chemical characterization 
> Develop and validate robust analytical methods 
> Scale-up manufacturing process 
> Optimize and validate process and controls 
> Minimize cost of goods 
> Formulation development 
> Select/validate appropriate container/closure system 
> Set appropriate control and release specifications 
> Define expiration dating (stability/compatibility) 
> Design label and outer packaging 
> Provide for adequate warehousing and distribution 
purity of ingredients, as well as those formulated products. Stability testing 
facilitates the establishment of recommended storage conditions, determination of 
retest periods and definition of acceptable shelf life. These data play a key role in 
determining labeling requirements, as well as in the development and monitoring 
process. 
Stability testing is performed on drug substances and products at various 
stages of product development (Table 1.2). In early stages, accelerated stability 
testing (at relatively high temperatures and/or humidities) is used as a "worst case" 
evaluation to determine what types of degradation products may be found after long-
term storage. In preformulation studies, interactions between excipients and the drug 
substance are studied under stress conditions to access compatibility. 
The design of a complete stability-testing programme for a drug or 
nutraceutical product is based upon an understanding of the behaviour, properties 
and stability of the drug substance or active ingredient and the experience gained 
from preformulation studies and early clinical formulations. Products are analysed at 
specific intervals to evaluate a variety of parameters, such as the identity of the 
active ingredient, potency, measurement of degradation products, dissolution time, 
physical properties and appearance. Samples from production lots of approved 
products are retained for stability testing and for comparison testing in the case of 
product failure. Testing of retained samples alongside returned samples is key to 
ascertaining whether the product failure was manufacturing or storage related. 
The objective of analytical testing during preclinical evaluation and Phase I 
clinical development is to evaluate the stability of the investigational formulations 
used in initial clinical trials, to obtain information needed to develop a final 
formulation and to select the most appropriate container and closure (e.g.. 
Table 1.2: Chemistry, Manufacturing and Controls Testing Conducted in the 
Drug Development Pathway 
Discovery to Phase I 
> Active pharmaceutical ingredient (API) solubility studies 
> API identification by spectroscopic analysis 
> Chromatographic purity 
> pKa determination 
> Moisture determination 
> Partitioning studies 
> Characterization studies 
> Development of chromatographic analysis of API 
> Residual solvents indentification and quantitation 
> Short-term stability of API 
> Reference standard certification 
Phase I 
> Validation of analytical methods for API and Phase 1 product 
> Stability of Phase I product 
> Release of Phase I clinical test materials 
Phases 11 and III 
> Continued analytical method refinements and validations as 
per product and process improvements 
> Release of Phase II and III clinical test materials 
> Release of product for long-term toxicology studies 
> Long-term stability program 
> Cleaning validation support 
> Analysis of manufacturing process validation samples 
> Container/closure extractable/leachable studies 
Post Approval 
> QC release of product 
> QC release of API 
> QC release of excipients 
> Post approval stability programs 
> Scale-up and post approval changes 
compatibility studies of potential interactive effects between a drug substance and 
other components). Information from the experiments listed in Table 1.2 under 
discovery to Phase I is summarized in the investigational new drug application 
(IND) with the initiation of Phase I clinical trials. When the delivery mechanism of 
the drug is an integral part of creating the therapeutic effect and must be used in the 
Phase I trials, formulation data, container closure data and corresponding short-term 
accelerated stability data should be included in the IND prior to Phase I trials. 
Analysis studies on formulations should be underway by the end of Phase 11 
and the stability protocol for study of both the drug substance and drug product 
should be defined. This will help assure that analytical chemistry data generated 
during Phase III are appropriate for submission. Prior to Phase I, stability of the drug 
substance and the formulation to be used must be evaluated. Impurities from the 
manufacturing and degradants that form are quantitated and tracked to ensure safety 
prior to moving into the Phase I clinical trials and continuity of material used for 
laboratory safety testing and clinical trials. 
Stability testing done during Phase III studies focuses on testing final 
formulations in the proposed packaging produced at the manufacturing site. It is 
recommended that the stability protocol is defined prior to the initiation of Phase III 
studies. In this regard, consideration should be given to establish appropriate linkage 
between the non-clinical and clinical batches of the drug substance and drug product 
and those of the primary stability batches in support of the proposed expiration-
dating period. Factors to be considered include the source, quality and purity of 
various components of the drug product, manufacturing process and production 
facility for the drug substance and the drug product, as well as use of same 
containers. Data obtained on tests done under controlled conditions replicating 
conditions recommended for long-term storage and slightly elevated temperatures 
are used to determine a product's shelf life and expiration dates. 
The stability of a product may be defined as the extent to which a product 
retains, within specified limits, throughout its period of storage and use, the same 
properties and characteristics possessed at the time of its packaging. Stability testing 
provides evidence on how the quality of a drug substance or drug product varies 
with time under the influence of a variety of environmental factors such as 
temperature, humidity and light. These studies are designed to determine if a drug 
substance will remain within specifications during its shelf life if stored under 
recommended storage conditions. 
Stability testing focuses on the chemical (i.e., integrity, potency, 
degradation) and physical properties (e.g., appearance, hardness, particle size, 
solubility) of active pharmaceutical ingredients (API) and products. In addition, 
microbiological testing is done to ensure the substance and product maintain their 
resistance to microbial and bacterial growth. Assuring the physical/chemical 
properties and effectiveness properties of a pharmaceutical is critical for labeling 
and marketing purposes. A wide range of testing is used to evaluate and verify the 
identity, potency and availability of the API in the product (Table 1.3). Stabilit>' 
testing is done at all phases of the development, production and marketing process 
for quality control and monitoring purposes. Early in the development of the drug 
product, purposeful degradation studies are done as a means to predict possible 
degradation pathways of an API. This information is used in the validation of 
stability indicating analytical methods and in pre-forinulation studies. Degradation 
studies include stress conditions such as heat, oxidative, light, acidic conditions, 
Table 1.3: Components of Stability Testing Protocol 
> Technical grade and manufacturer of drug substance and excipients 
> Type, size, and number of batches 
> Type, size, and source of containers and closures 
> Test parameters 
> Test methods 
> Acceptance criteria 
> Test time points 
> Test storage conditions 
> Container storage orientations 
> Sampling plan 
> Statistical analysis approaches and evaluations 
> Data presentation 
> Retest or expiration dating period 
> Stability commitment 
basic conditions and heat/humidity. Testing to assure that products meet 
specifications for the presence of degradation products and impurities are usually 
intensive chromatographic separations with detection down to the 0.01% levels. 
Typically, impurities and degradation products that are 0.1% and above need to be 
evaluated for identity and chemical structure. The level of the impurities allowed 
depends on the toxicity of the impurity and the daily dose levels of the drug. Identity 
information on the stability of a drug substance under defined storage conditions is 
an integral part of the systematic approach to stability evaluation. Stress testing 
helps to determine the intrinsic stability characteristics of a molecule by establishing 
degradation pathways to identify the likely degradation products and to validate the 
stability indicating power of the analytical procedures used. 
The severe conditions encountered during distribution are covered by 
stress testing of definitive batches of the drug substance. Stress testing provides data 
on forced decomposition products and mechanisms. These studies establish the 
inherent stability characteristics of the molecule (e.g., degradation pathways) and 
lead to identification of degradation products and support the suitability of the 
proposed analyfical procedures. The detailed nature of the studies will depend on the 
individual drug substance and type of drug product. 
Testing is carried out on a single batch of a drug substance and includes the 
effects of temperatures in 10°C increments above the accelerated temperature test 
condition and humidity, where appropriate (e.g., 75 % or greater). In addition, one 
must evaluate oxidation and photolysis on the drug substance, plus its susceptibility 
to hydrolysis across a wide range of pH values when in solution or suspension. 
Photostability (i.e., light) testing is an integral part of stress testing. Some 
11 
degradation pathways can be complex and, under forced conditions, decomposition 
products may be observed that are unlikely to be formed under accelerated or long-
term testing. This information is useful in developing and validating suitable 
analytical methods, but may not be necessary to examine specifically for all 
degradation products if it has been demonstrated that in practice these are not 
formed. Information obtained from photostability is key in choosing appropriate 
container/ closure system. 
The route of administration and deliver)' system used are key components to 
the successful development of new drugs and therapies. In addition, these choices 
have a significant impact on the scientific and regulatory aspects of a stability 
protocol. The diversity of testing needed for all dosage forms and delivery systems 
requires a broad range of expertise and methodologies. 
In general, all dosage forms are evaluated for appearance, assay and 
degradation products. Additional tests (i.e., potency) are needed for specific dosage 
forms. For example, sterility is needed for sterile products but not for tablets or 
capsules. In addition, not every test will be performed at each time point. 
Purity, a metaphysical concept, has always been considered as an essential 
factor in ensuring drug quality. Absolute purity does not exist and the degree of 
purity of a product is only a reflection of the analytical techniques used for its 
assessment. All pharmaceutical substances unavoidably contain impurities resulting 
from many sources like raw materials and reagents, as reaction byproducts and 
through degradation during manufacture and storage or extraneous contamination. 
The presence of these unwanted chemicals even in small amounts may influence the 
efficacy and safety of the pharmaceutical products. The different pharmacopoeias, 
such as the British Pharmacopoeias (BP) and the United States Pharmacopoeias 
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(USP) are slowly incorporating limits to allowable levels of impurities present in the 
APIs or formulations. Also, the ICH has published guidelines on impurities in new 
drug substances [3], products [4], and residual solvents [5]. In addition, Ahuja [6] 
and Gorog [7] have published books covering different aspects of impurities, 
including the governmental regulations and guidelines and the identification and 
monitoring of impurities found in drug products. 
A number of recent articles [8-10] have described a designed approach and 
guidance for identifying process related impurities and degradation products using 
mass spectrometry, NMR, high performance liquid chromatography, fourier 
transform ion cyclotron resonance mass spectrometry and tandem mass spectrometry 
for pharmaceutical substances. In general, according to ICH guidelines on impurities 
in new drug products [4], identification of impurities below the 0.1% level is not 
considered to be necessary unless the potential impurities are expected to be 
unusually potent or toxic. There are two types of impurities in medicines: 
• impurities associated with active pharmaceutical ingredients 
• impurities that are created during formulation and/or with aging or that are 
related to the formulated forms. 
According to ICH guidelines [4], impurities associated with APIs are classified into 
three classes for regulatory purpose as organic, inorganic and residual solvents. 
• Organic impurities may arise fi-om starting materials (most often from 
isomeric impurities), synthetic intermediates (incomplete reaction or excess 
reagent used) and degradation product which may depend on alteration in 
reaction conditions such as temperature, pH or in storage condition 
(hydrolysis, ring opening etc.). 
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• Inorganic impurities present in pharmaceutical products originate from the 
equipment used and from reagents, catalysts, drying agents and filter aids. 
• Residual solvents and other volatile impurities must be detected and 
assayed, not only because of their potential toxicity and deleterious 
environmental effects, but also because they can impart undesirable 
organoleptic characteristics to drugs. 
The increasing emphasis on the pharmacokinetics, bioavailability and 
therapeutic monitoring of drug has placed a heavy burden on drug analyst. Thanks to 
advances in analytical instrumentation and a greater understanding of metabolism, 
we can now detect drugs at concentrations that were once undetectable. Because of 
the vast number of drugs introduced every year, more and more methods for drugs 
and metabolite determination are being developed either for routine or research use. 
Analytical procedures are used throughout the drug development and manufacturing 
of drug substances and drug products. 
The application of increasingly sophisticated methods for structure analysis 
by spectroscopy, isotopic labeling, automated quantitative analysis and separation by 
chromatography and other partition procedures opened avenues of study of minute 
amounts of biochemicals. Instrumental analysis opened many doors to scientific 
progress in support of both traditional core areas of chemistry and new ones like 
biotechnology, material chemistry, environmental chemistry, chemical toxicology 
and small domain chemistry. 
In the field of drug analysis, volumetric methods, either direct or indirect, 
have their own importance due to their inherent simplicity. Owing to this, a large 
number of official methods for the determination of pharmaceuticals in the 
pharmacopoeias are based on titrimetry. Though it is the oldest technique in the 
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market now but still have their recognition in the field of scientific research. 
Recently titrimetric methods have been used for the determination of albendazole 
[11], gatifloxacin [12], promethazine theodate [13] and nizatidine [14] in 
commercial dosage forms. 
Chromatographic methods have many applications in trace analysis. The 
different types of chromatography such as thin layer chromatography, column 
chromatography, high performance liquid chromatography, gas chromatography and 
capillary electrochromatography have most frequent applications in the field of 
pharmaceutical as well as biomedical analyses. 
Thin layer chromatography (TLC) is simple, rapid, inexpensive and widely 
used for the separation and identification of pharmaceuticals. A TLC method has 
been developed for the determination of oxysterols in plasma using plates coated 
with either RP-C18 or silica gel F34 [15]. This technique has also been used to 
analyse celecoxib in commercial dosage forms [16]. The contents of gestodene and 
cyproterone have been determined in raw material and dosage forms by thin layer 
chromatography [17]. 
High performance thin layer chromatography (HPTLC) is a fast separation 
technique and flexible enough to analyse different kinds of samples. Review papers 
[18,19] by Renger have discussed the potential of TLC and HPTLC in 
pharmaceutical analysis. The advantages associated with this technique are as 
follows: 
• simple to handle the instruments. 
• short analysis time to analyse complex or crude sample with minimum 
sample clean up. 
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• evaluate the entire chromatogram with a wide variety of techniques and 
parameters without time constraints. 
• simultaneous but independent development of multiple sample and standards 
on each plate, leading to an increased reliability of results. 
• robustness for easy transfer of samples. 
Several drugs have been successfully investigated by HPTLC in 
pharmaceutical preparations [20-23]. 
High performance liquid chromatography has gained lots of attention 
recently in the field of drug analysis in both dosage forms and biological fluids 
because of its simplicity, high specificity and sensifivity. For example, captopril can 
be measured in pharmaceutical tablets by anion exchange HPLC using indirect 
photometric detection [24]. The method is also used in the determination of 
alprazolam [25] and buspirone [26] in pharmaceutical formulations. Dexamethasone 
has been estimated by HPLC using isocratic reversed phased procedure in cream 
formulations [27]. This method can also be used to measure impurities [28,29], 
degradation products [30,31] and product preservatives at levels between 0.05 and 
0.1%. HPLC assay procedures have been developed for cephalexin and cefadroxil, 
cefaclor and cefataxim in pharmaceuticals [32] and for cefixime trihydrate in bulk 
drugs [33]. 
Because of the specificity and sensitivity afforded by gas chromatography, it 
has been widely used for the detection and determination of trace level contaminants 
in pure substances and also in pharmacokinetic studies. The use of mass 
spectrometer as the gas chromatographic detector provides additional sensitivity 
and specificity over other analytical methods [34]. A number of papers have been 
published on the application of gas chromatography in pharamaceutical analysis 
both in dosage forms and biological fluids [35-37]. The method was also used for 
the determination of isotretinoin and its degradation products in pharmaceuticals 
[38]. 
In flow injection analysis (FIA) a quantity of dissolved sample, accurately 
measured, is injected or introduced into the carrier stream flowing through the 
system tubing, with or without additional changes like chemical reactions etc. 
occurring between the sample and the carrier. As the analyte passes continuously 
through the detector, a transient signal is generated and recorded. The main reasons 
for the success are the following advantages of FIA over conventional manual 
techniques: 
• great precision due to mechanical performance of the assays. 
• reduced labour costs due to automation. 
• higher sample throughput due to mechanical performance of the assay. 
• small sample and reagent consumption and waste generation due to smaller 
scale of the assay 
This technique has been utilized successfully in the determination of some 
compounds of pharmaceutical interest [39-41]. Later on, FIA evolved in sequential 
injection analysis (SIA) [42]. The introduction of SIA brought computer control into 
flow injection, thus increasing the degree of automation and making the technique 
more versatile. 
Capillary electrophoresis (CE) is an automated analytical technique that 
separates species by applying voltage across buffer filled capillaries. It is generally 
used for separating ions, which move at different speeds when the voltage is applied 
depending on their size and charge. The solutes are seen as peaks as they pass 
through the detector and the area of eqch peak is proportional to their concentration. 
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which allows quantitative determinations. Analysis includes purity determination 
assays, and trace level determinations. Pharmaceutical companies make extensive 
use of CE [43] and are widely accepted by regulatory authorities such as US food 
and drug administration [44-47]. CE methods have often replaced existing titration 
and ion-exchange chromatographic (lEC) methods because they are often faster, 
more efficient and cost effective. Another benefit is that the analysis performed on 
standard CE instrumentation and does not require extra lEC equipment, columns and 
reagents. One area where CE has distinct advantage over other separation techniques 
is chiral analysis. Chiral separations are among the most widely used application of 
CE [48]. Several reports have appeared on the application of this technique in 
different modes such as capillary zone electrophoresis [49], micellar electrokinetic 
chromatography [50], isotachophoresis [51], capillary electrokinetics [52], capillary 
gel electrophoresis [53], iso-electric focusing [54] and affinity capillary 
electrophoresis [55]. 
Electrochemical methods are concerned with the measurements of electrical 
quantities such as (i) voltage (V), (ii) current (I), (iii) charge (Q) and (iv) resistance 
(R) to gain information about the composition of the solution and the reaction 
kinetics of its components, important electrochemical techniques such as 
amperometry, conductometry, potentiometry, coulommetry, anodic and cathodic 
stripping voltammetry [56-58], differential pulse voltammetry and poiarography 
have been used in drug analysis [59, 60]. Potentiometric titrations are also reported 
in the pharmacopoeias as the standard method for the determination of certain drug 
substances [61-63]. 
Spectroscopic methods are widely used for the assay of drugs in 
pharmaceutical formulations. The most commonly used technique for quantitative 
analysis are ultraviolet (UV) and visible spectrophotometry. The simplicity of UV-
spectrophotometry is best known and most widely accepted for qualitative and 
quantitave analyses. Conventional UV-spectrophotometric methods are simple, fast 
and economical and do not need any elaborate preparatory step prior to assay. 
However, these methods are inadequate when two or more drugs showing similar 
UV spectra in the presence of other components in the drug sample like excipients 
or decomposition products. 
Photometric methods of analysis are performed in the visible region of light. 
These methods are usually based on the following aspects: 
• oxidation-reduction process. 
• complex-formation reaction. 
• a catalytic effect. 
In each type of reaction the absorbance of coloured compounds is measured. 
Usually, the analytes under investigation are colourless, they are reacted with 
suitable chemical reagents in order to convert them in coloured compounds. Simple 
colorimetric and UV methods continue to be popular for carrying out single 
component assays on a variety of formulated products. Representative examples of 
UV-visible methods of drug analysis for some pharmaceuticals that have been 
published [64-107] are given in Table 1.4. 
In the course of this discussion, the importance of computer-aided 
spectrophotometric determination of multicomponent systems cannot be ignored. 
Pharmaceutical preparations are usually mixtures of the active principal and various 
excipients that absorb in the same region as the component of interest, thereby 
resulting in band overlap and impeding the use of the technique with simple 
calibration methods. The inception of microcomputers and spectrophotometers that 
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Table 1.4: Assay of drugs in pharmaceutical 
spectrophotometric procedures. 
formulation by UV-visible 
Name of drugs 
Acetaminophen 
Amiodarone HCI 
Amiodipine 
besylate 
Amoxycillin 
Ampicillin 
Ascorbic acid 
Benidipine HCI 
Captopril 
Carbenicillin 
Diclofenac sodium 
Diltiazem HCI 
Famotidine 
Flunarizine 
Reagents used 
w-cresol 
jfj-chloranilic acid 
2,3-dichioro-5,6-dicyano-1,4-
benzoquinone 
p-chloranilic acid 
ninhydrin in DMF medium 
2,3-dichloro-5,6-dicyano-l,4-
benzoquinone 
ascorbic acid 
1, 10-phenanthroline 
2, 2 -bipyridyl 
ammonium heptamolybdate 
potassium iodate 
folin-ciocalteau phenol reagent 
potassium iodate 
folin-ciocalteau phenol reagent 
1 -chloro-2,4-dinitrobenzene 
methanol 
potassium iodate 
folin-ciocalteau phenol reagent 
tris buffer 
sodium metavanadate 
bromophenol blue 
bromothymol blue 
bromocresol green 
KMn04 in alkaline medium 
ninhydrin 
iodine 
Ama,(nm) 
640 
535 
575 
540 
595 
580 
530 
500 
515 
825 
520 
770 
520 
750 
380 
238 
510 
750 
284, 305 
750 
415 
415 
415 
610 
590 
295,355 
References 
64 
65 
65 
66 
67 
68 
68 
69 
69 
69 
70 
71 
70 
71 
72 
73 
74 
71 
75 
76 
77 
77 
77 
78 
79 
80 
dihydrochloride 
Labetalol 
hydrochloride 
Levodopa 
Lisinopril 
Menadione 
Methyldopa 
Metoprolol 
sodium nitroprusside 695 
Ce (IV) nitrate in H2SO4 medium 
NaOH 
Ninhydrin 
ascorbic acid 
NaOH in presence of amine 
ethyl acetoacetate and ethanolic 
ammonia 
Ce (IV) nitrate in H2SO4 medium 550 
ninhydrin in DMF 595 
KMnOa in alkaline medium 610 
81 
510 
300 
690 
530 
450 
550 
82 
82 
83 
83 
84 
85 
82 
86 
87 
Mometasone methanol 248 88 
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furcate 
Nalidixic acid 
Nicorandil 
Nifedipine 
Norfloxacin 
Ofloxacin 
Pantoprazole 
Ramipril 
Roxatidine acetate 
hydrochloride 
Silymarin 
Trimethoprim 
Thyroxine 
Verapamil 
persulfate in alkaline medium 
brucine-sulfanilic acid in H2SO4 
medium 
3-methyl-2-benzothiazolinone 
hydrazone hydrochloride and metol 
phloroglucinol-sulfanilic acid in 
H2SO4 medium 
3-methyl-2-benzothiazolinone 
hydrazone hydrochloride and DL-
3,4-dihydroxyphenylalanine 
KMn04 in neutral medium 
4-methyl amino phenol and K2Cr207 
bromocresol green 
bromophenol blue 
bromothymol blue 
eriochrome black-T 
KOH in dimethylsulfoxide 
KMn04 in alkaline medium 
bromocresol purple 
bromocresol blue 
1 -flouro-2,4-dinitrobenzene 
potassium iodide and potassium 
iodate 
2,3-dichloro-5,6-dicyano-l,4-
benzoquinone 
p-chloranilic acid 
KMn04 in neutral medium 
3-methyl-2-benzothiazolinone 
hydrazone hydrochloride and 
potassium persulfate 
persulfate in alkaline medium 
nitrous acid 
chloramine-T 
N-bromosuccinimide 
potassium metaperiodate in H2SO4 
medium 
tropaeolin 000 No.l at pH 4.0 
320, 390 
410 
560 
425 
530 
89 
90 
90 
91 
91 
530 
525 
415 
415 
415 
520 
430 
603 
408 
414 
420 
352 
530 
530 
530 
430 
355 
420 
425 
415 
425 
92 
93 
94 
94 
94 
94 
95 
96 
97 
98 
99 
100 
100 
101 
102 
103 
104 
105 
106 
107 
400 107 
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allow absorbance spectra to be expeditiously recorded at many wavelengths has 
enable the development of analytical methods based on the mathematical resolution 
of multivariate signals for the rapid quantitation of mixtures of analytes in control 
analyses. The application of multivariate calibration methods to spectral data in 
biomedical and pharmaceutical fields has acquired a routine nature [108-112]. 
Partial least square (PLS) has several advantages of using full spectra, which is 
critical for the spectroscopic resolution of complex mixture of analyte. It allows for 
a rapid determination of components usually with no need of a prior separation. An 
additional advantage of PLS is that calibration can be performed by ignoring the 
concentrations of all other components except the analyte of interest. The 
complementary use of PLS multivariate calibration and artificial neural network for 
the simultaneous spectrophotometric determination of three active components such 
as chlorpheniramine, nephazoline and dexamethasone in a pharmaceutical 
formulation has been successfully explored [113]. 
Derivative spectrophotometry is an analytical technique of great utility for 
both qualitative and quantitative information from spectra composed of unresolved 
bands. Although it was introduced for more than thirty years ago [114-118] and has 
advantages for the solution of specific analytical problems. The derivative methods 
have found applications not only in the UV-visible spectrophotometry [119], but 
also in infra-red [120], atomic absorption [121], flame emission spectrometry [122] 
and flourimetry [123]. The use of derivative spectrophotometry is not restricted to 
special cases, but may be of advantage whenever quantitative study of normal 
spectra is difficult. Its disadvantage is that the differentiation degrades the signal-to-
noise ratio, so that some form of smoothing is required in conjunction with the 
differentiation [124,125]. 
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Near infra red (NIR) spectroscopy is a technique which has found its way 
into pharmaceutical control laboratories in recent years for raw material 
identification, water analysis and other pharmaceutical analyses [126-129]. NIR has 
the potential to dramatically improve the quality of drug manufacturing. There are 
several advantages associated with this technique such as reduction in the cost of 
testing, require no reagents, associated reagents preparation steps, sampling 
preparation steps and generally require only one working analyst day to complete 
testing. The United State Pharmacopoeia has proposed guidelines [130,131] for this 
technique. 
Nuclear magnetic resonance (NMR) spectroscopy has been mainly used for 
the elucidation and confirmation of structures. For the last decades, NMR methods 
have been introduced to quantitative analysis in order to determine the impurity 
profile of a drug, to characterize the composition of drug products in body fluids, in 
solid state measurements to provide the information and for micro-imaging to study 
the dissolution of tablets [132-136]. 
Flourimetry and phosphorimetry find wide applications in quantitative 
studies of rates of degradation, metabolism and excretion of drugs where other 
analytical techniques are not sufficiently sensitive. A gradual increase in the number 
of papers on the potential application of flourimetry and phosphorimetry in the field 
of pharmaceutical analysis has been noticed during the last few years [137-141]. 
In the recent period, analysts are much interested in coupling the 
chromatographic techniques with spectroscopic techniques. The advent of liquid-
liquid chromatography with mass spectrometry [142-144], gas chromatography with 
tandem mass spectrometry and liquid chromatography-electrospray tandem mass 
spectrometry are good examples. Hirsch and coworkers have determined the 
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antibiotics using chromatography-electrospray tandem mass spectrometry [145]. 
Dielectric relaxation spectroscopy and X-ray powder differactometry are also 
utilized for the identification of pharmaceuticals [146]. 
Kinetic automatic methods are good choices for drug analyses as they pennit 
the sensitive, selective determination of many drugs within a few seconds with no 
pretreatment. Moreover, the instrumentation required is generally very simple. 
Kinetic methods rely on measurement of concentration changes (detected via signal 
changes) in a reactant (which may be the analyte itself) with time after the sample 
and the reagents have been mixed. The sample and reagent can be mixed manually 
or automatically and the kinetic curve (variation of analytical signal with time) can 
be recorded immediately. The slope of the straight initial portion of the kinetic curve 
gives the reaction rate, which is proportional to the analyte concentration (initial-rate 
method). The fixed-time method also frequently used to derive such a concentration, 
involves measuring the signal (the value of which depend on the analyte 
concentration) at a pre-set time. The fixed-time and initial-rate methods have been 
used more frequently for the determination of drugs in pharmaceutical formulations 
and biological fluids [147-149]. Kinetic is relevant to analytical chemistry in at least 
four respects: 
• it allows the elucidation of the physical, chemical and physico-chemical 
mechanisms on which analytical processes are based and hence their rational 
optimisation. 
• it facilitates the development of new analytical methods that are otherwise 
unattainable if the dynamic aspects are not dealt with. 
• it is the foundation of reaction rate method. 
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• it contributes to the improvement of significant analytical parameters sucii as 
sensitivity, selectivity and precision. 
Whenever the question of mathematical and statistical treatment arises, the 
role of chemometrics cannot be ignored. Chemometrics is defined as "the chemical 
discipline that uses mathematical, statistical and other methods of formal logic to 
design or select optimal procedures and experiments and provide maximum 
chemical information by analysing chemical data" [150-152]. Chemometrics is the 
science that helps to make good use of information technology in the chemical 
analysis and to develop intelligent analysers i.e. that automatically select the correct 
method for a given problem, carry it out, validate it and interpret the results. 
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METHOD VALIDATION STRATEGY 
Before an analytical method can be used for routine analysis, it must first be 
demonstrated that the method fulfills certain performance criteria. When this has 
been documented, the method is said to be validated. In order to address the 
performances of the analytical procedure adequately, the analyst is responsible to 
identify the relevant parameters, to design the experimental validation studies and 
define the appropriate acceptance criteria. The purpose of method validation is to 
establish that an accurate, precise and rugged method has been developed. The 
process for the development, validation and use of analytical method is shown in 
Fig. 1.2. 
The validation of analytical methods used in bioavailability, bioequivalence 
and pharmacokinetic studies in human and animals has been the subject of 
discussion in recent years [153-158]. Several International Organisations and 
Regulatory Authorities, which are involved in fixing the criteria for the validation, 
are listed in Table 1.5. It has been agreed that the following parameters must be 
considered for evaluation of method reliability and overall performances: 
confirmation of identity 
analyte stability 
selectivity/specificity 
precision and accuracy 
limit of detection and quantitation 
recovery 
robustness/ruggedness 
The overall validation strategy consists of four components, which are prevalidation 
[159,160], proper validation [161,162], study proper and statistical analysis. 
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Define performance 
specifications 
Devise development 
experiments 
Execute and evaluate 
results 
Plan method validation 
experiments 
Calibration model, 
range and linearity 
Precision and 
accuracy 
Analyte stability 
Collate results 
Write validation report 
Apply validated 
method 
Fig.1.2: The process of development, validation and routine use of an 
analytical method. 
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Table 1.5: Validation of analytical methods International deflnitions. 
Organisation 
lUPAC 
ILAC 
WELAC 
ICH 
ISO 
Applicability 
World wide 
World wide 
Europe 
Europe, Japan, USA 
World wide 
Remarks 
Only pharmaceutical products 
Lack definition of selectivity 
and specificity 
Abbreviations: 
lUPAC, International Union of Pure and Applied Chemistry. 
ILAC, International Laboratory Accreditation Conference. 
WELAC, Western European Laboratory Accreditation Co-operation 
ICH, International Conference on Harmonization. 
ISO, International Organization for Standardization. 
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Confirmation of identity 
In general analytical methods consist of a measurement stage, which may be 
preceded by an isolation stage. It is necessary to establish that the signal or reaction 
produced at measurement stage is only due to analyte and not due to something 
chemically or physically similar or arising as a coincidence. This is the confirmation 
of the identity, whether or not other compounds interfere with the measurement of 
the analyte will depend on the effectiveness of the isolation stage if it was part of the 
method, as well as the specificity/selectivity of the measurement stage. 
Selectivity/Specificity 
Selectivity is the ability of an analytical method to differentiate and quantify 
the analyte in the presence of other components in the sample. Selectivity should be 
ensured at the lower limit of quantification (LLOQ) [163-165]. The term 'specific' 
generally refers to a method that produces a response for single analyte. 
Accuracy and Precision 
The accuracy [166] of a method is defined as the closeness of agreement 
between the test results and the accepted reference value. This is sometimes termed 
trueness. 
According to ICH, the precision is the closeness of agreement (degree of 
scatter) between a series of measurements obtained from multiple sampling of the 
same homogeneous sample under the prescribed conditions and may be considered 
at three levels: 
• repeatability 
• intermediate precision 
• reproducibility 
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Repeatability 
Repeatability is the precision obtained by independent test results with the 
same method on identical test material in the same laboratory by the same operator 
using the same equipment within short interval of time. It is also termed as intra-
assay precision [167-168]. Repeatability is also sometimes termed as within run or 
within day precision. 
Intermediate Precision 
Intermediate precision expresses within-laboratories variations: different 
days, different analysts, different equipment etc. [159]. The International 
Organization for Standardization (ISO) definitions used the term "M-factor different 
intermediate precision" where the M-factor expresses the number of factors 
(operator, equipment or time) that differ between successive determination [169]. 
Intermediate precision is sometimes also called between-run, between-day or inter-
assay precision. Several approaches discussed in ICH guidelines are given in 
Table 1.6. 
Reproducibility 
Reproducibility is the precision obtained within the same method on 
identical test material in different laboratories with different operators using 
different equipments [170]. 
Limit of detection and quantitation 
Limit of detection (LOD) determines the lowest amount of analyte that can 
be detected, as it (the analyte) yields instrumental response greater than a blank, but 
cannot be quantified. The common definition of LOD is the concentration (or 
quantity) of analyte that produces a signal, that exceeds the signal observed from a 
Table 1.6: Quantitave approaches to demonstrate accuracy according to ICH. 
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Drug Substance 
Drug Product 
Impurities 
(Quantitative) 
Application of the analytical procedure to a reference material. 
Comparison of the results with those of a second, well 
characterised procedure. 
Application of the analytical procedure to synthetic mixtures 
of drug product components. 
Spiking of analyte to drug product. 
Comparison of the results with those of a second, well 
characterised procedure. 
Spiking of the impurity to drug substances or product. 
Comparison of the results with those of a second, well 
characterised procedure. 
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blank by an amount equal to three times the standard deviation from the 
measurement on the blank [162]. 
A limit of quantitation (LOQ), defined as the analyte concentration for which 
the signal exceeds that for a realistic analytical blank by ten times the standard 
deviation, is often specified as the smallest analyte concentration that one should 
attempt to quantify [164]. Several approaches have been given in the ICH guidelines 
to determine the detection and quantitation limits (Table 1.7). 
Calibration range and Dynamic range 
The calibration range will be defined by the expected concentration in the 
samples and will be usually in the linear range of the detector for that analyte, where 
the determined response is directly proportional to the concentration interval over 
which acceptable accuracy, linearity and precision are obtained. In practice the range 
is determined using data from the linearity and accuracy studies. 
Fig. 1.3 illustrates the definition of the dynamic range of an analytical 
method, which extends from the lowest concentration at which quantitative 
measurements can be made to the concentration at which the calibration curve 
departs from linearity (limit of linearity). 
Recovery 
The recovery is a measure of all efficiency of the method in detecting all the 
analyte of interest present in the original sample. Recovery should be as high as 
possible, but is more important that it (recovery) is constant within the calibration 
range [173]. 
Robustness/Rugged ness 
ICH [174] defines the '•robustness/ruggcdness" of an analytical procedure as 
a measure of its capacity to remain unaffected by small, but deliberate variation in 
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Table 1.7: Approaches for determining the detection and quantitation limits 
[167]. 
Approach Detection limit Quantitation limit 
Visual evolution Minimum level detection Minimum level 
quantifiable 
Signal-to-noise 3: lor 2:1 10:1 
Standard deviation of the 
response (So)'' and the 
3.3 X (So)/b 10.0 X (So)/b 
slope(b) 
"Varification with suitable number of samples. 
''Standard deviation of the blank, or standard deviation of the calibration line. 
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[y] 
Instrumental 
response (signal) 
Signal blank 
Dynamic Range 
M • , 
Concentration [x] 
Fig. 1.3: Useful range of an analytical method: LOQ = Limit of quantitative 
measurement and LOL = Limit of linear response 
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method parameters and provides an indication of its reliability during normal usage 
[162-166]. Ruggedness is a measure for the susceptibility of a method to small 
changes that might occur during routine analysis like small changes of pH values, 
mobile phase composition, temperature etc. Full validation must not necessarily 
include ruggedness testing; it can, however, be very helpful during the method 
development/prevalidation phase, as problems that may occur during validation are 
often detected in advance. Ruggedness should be tested, if a method is supposed to 
be transferred to another laboratory [ 175]. 
STATISTICAL ANALYSIS 
Recent trends [176-179] in the pharmaceutical analysis emphasize the use of 
statistical analysis and evaluation of the method against statistical parameters like 
correlation coefficient, variance, errors and confidence limits, limit of detection and 
sensitivity, standard deviation, '/' and ' F ' values, standard deviation of slope and 
intercept etc. A brief discussion is given below. 
Correlation Coefficient 
When using instrumental methods, it is often necessary to carry out a 
calibration process by using a series of samples (standard) each having a known 
concentration of analyte. Two statistical procedures should be applied to the 
calibration curve: 
• test whether the graph is linear or in the form of a curve 
• find the best straight line (or curve) through the data points 
Linearity is often tested by correlation coefficient, 'r', which can be 
calculated for a calibration curve to ascertain the degree of correlation between the 
measured instrumental variable and the sample concentration. 
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where, 
X = mean of all the values of Xj 
y = mean of all the values ofyi 
n = number of data points. 
The maximum value of 'r' is 1. When this occurs there is exact correlation 
between the two variables (x and y). When the value of 'r' is zero (xy=0), there is 
complete independence of the variables. As a general rule, 0.90<r<0.95 indicates a 
fair curve, 0.95<r<0.99 as a good curve, and r>0.99 includes excellent linearity. 
Linear least squares 
The best straight line through a series of experimental points is that line for 
which the sum of the squares of the deviation of the points from the line is 
minimum. Besides determining a straight line, uncertainties in the use of calibration 
graph for analysis of unknown samples can be specified by the method of least 
squares. The equation of the straight line is 
A = a + bC 
Where 
A= instrumental response (i.e. absorbance), b=slope, a=intercept, and 
C=concentration 
To obtain the regression line A on C, the slope 'b' of the line and the 
intercept 'a' on the y-axis are given by the following equations 
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n 
where 
X\ = individual value of concentration 
_Vj =individual value of absorbance corresponding to Xj 
n = number of data points in the calibration line 
Error in the concentration 
The error (Sc) in the determination of the concentration of the analyte in the 
given sample can be calculated using the relation: 
T - l l / 2 
where x and y are the average concentration and absorbance values, 
' b 
respectively, for 'n' standard solutions. Standard deviation of the calibration line 
(So) is evaluated from the following equation: 
n-2 
Confidence limit for the slope and intercept 
It determines whether the slope and/or intercept of a line differ significantly 
from a particular or predicted value. It can be calculated as, 
b ± / Sb (for slope) 
and/or 
17 
a ± / Sa (for intercept) 
where 
/= tabulated't' value at desired confidence level for (n-2) degrees of freedom. 
Limits of detection and quantitation 
Limit of Detection (LOD)/ Limit of Quantitation (LOQ) are defined as the 
3.3 and 10 fold, respectively of the standard deviation of the calibration line. The 
values are converted to a concentration by the slope of a corresponding calibration 
line. 
So 
LOD = 3.3 X — b 
So 
L O Q - 1 0 X — 
Significance of testing 
An important property of an analytical method is that it should be free from 
the systematic error (bias). Determining bias involves analyzing one or more 
standard reference materials whose analyte concentration is known. However, 
random errors make it unlikely that, the measured amount will equal to the known 
amount even when no systematic errors are present. In order to decide whether the 
difference between the observed and standard values can be accounted for by 
random variation, a statistical test i.e. a significance test is used for the interpretation 
of analytical data. 
• Student's /-test: Here comparison is made between two sets of replicate 
measurements made by two different methods; one is the test method while 
other is accepted (reference method). 
+ ^ ^ ^ 1 - ^ 2 I «1«2 
Sp V «, + «2 
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where. 
X, = mean from the test method 
X2 = mean from the accepted (reference) method 
n\ & «2 = number of measurements 
Sp=pooled standard deviation of the individual measurements of two sets 
is given by 
A statistical /-value is calculated and compared with a tabulated value for the 
given number of tests at the desired confidence level. If /cai>^ ab then there is 
significant difference between the results obtained by the two methods at the given 
confidence level. But if /cai<^ tab then there is no significant difference between the 
methods. It is an accuracy-indicating test. 
• F-Test: This test indicates whether there is a significant difference between 
the two methods (i.e. the new method and the accepted reference method). It 
can be represented as, 
where 
Si and 82= standard deviation of method 1&2. 
The calculated value of 'F' is compared with the tabulated standard value at 
the selected confidence level and degrees of freedom. If Fcai>i^ tab then there is 
significant difference between the two methods. It is a precision indicating test. 
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Interval hypotheses 
For practical purposes, the acceptable bias can be calculated statistically 
[180]. 
For example, a test method (method 2) is considered acceptable if its true mean 
value is within that of the reference method (method 1), i.e. 
-0.02 n,< (^2- ^i) < 0.02 Hi 
this can be written as 
0.98 <H2/Hi< 1-02 
which can be generalised to 
OL < ^2/^1 < Ou 
where 6L and 9u represents the lower and the upper acceptance limits, 
respectively when |i2 is expressed as the proportion of the reference mean \i]. 
Statistically, 0L and 9u can be calculated from the relation 
r 
B' - 2 '^p'-tab 
V n 
r 
-20XiX2 + 
1 J 
:2 _ n r t ab 
•2 = 0 
The lower limit (9L) and the upper limit (6u) of confidence interval are obtained 
as 
where. 
0 _-b-VS^ 
^' 2a 
^ -b+Vb^ 
2a 
^ . 2 . 2 
- 2 '^p'-tab 
a = X, 
" i 
b = -2x,X2 
-4ac 
-4ac 
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— 2 '-'p'-tab 
C = X 2 
" 2 
where x, and Xj estimates of |J.I and |i2 based on ni and n2 measurements 
respectively. Sp is the pooled standard deviation and /tab 's the tabulated one sided 
/-value, with ni+n2-2 degrees of freedom at the specified level of significance. 
Testing for outliers 
When a series of replicate measurements of same quantity are made, one of 
the results will appear too different markedly from the other. There is then a great 
temptation to discard this "outliers" before calculating the mean and the standard 
deviation of the data or applying statistical tests to compare the data with other 
measurements. The best known method for this purpose is Dixon's Q-test. 
_ I Suspected value - Nearest value | 
[Largest value - Smallest value] 
If Qcai>Qtab at a given confidence level, then the outliers can be rejected. 
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CLASSIFICATION OF DRUGS 
The drugs can be prepared synthetically or reconstituted from natural sources 
product. All the drugs having medicinal importance can be classified considering 
their structures and pharmacological properties. 
Chemical classification 
The drugs are classified according to their chemical structure and properties 
without taking the pharmacological action. In this class most of the drugs are having 
at least an organic substrate; further classification is done in the relevant manner. 
Pharmacological classification 
In this class the drugs are divided according to their action on the organism's 
organ (viz. heart, brain, lymphatic system, respiratory system, endocrine system, 
central nervous system etc.) Hence these drugs are called cardiovascular, narcotics, 
analgesics, antibiotics, diuretics, and anaesthetics etc. Further classification of each 
group is done according to the therapeutic/pharmacological specificity with the 
relevant organ. A detailed classification of drugs based on pharmacological action 
on human organs has been given in Scheme 1.1. 
The present thesis deals with the determination of captopril, lisinopril 
dihydrate, labetalol hydrochloride and perindopril erbumine in pharmaceutical 
formulations. 
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CAPTOPRIL (C9H 15NO3S) 
COOH 
I 
Captopril, l-[(2S)-3-mercapto-2-methyl-propionyl]-L-proline, is a 
sulphahydril containing angiotensin converting enzyme inhibitors (ACE) which 
reduces peripheral resistance and lowers blood pressure. It is widely used in the 
hypertensive ailments and in congestive heart failure treatment. Captopril lowers 
blood pressure, but in the short term magnitude of response is independent of Na^ 
status and the level of renin-angiotensin activity. A greater fall in blood pressure 
occurs in renovascular, accelerated and malignant hypertension. However, in the long 
term no correlation has been observed between plasma renin activity and intensity of 
fall in blood pressure due to captopril. Captopril induced hypotension is a result of 
decrease in total peripheral resistance. The arterioles dilate and compliance of larger 
arteries is increased. It is also used to treat kidney problems in some diabetic patients 
who use insulin to control their diabetes. Captopril was the first ACE inhibitor 
developed and was considered a break through both because of its novel mechanism 
of action and also because of the revolutionary development process. 
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LISINOPRIL DIHYDRATE (CziHjiNsOs • 2 H2O) 
COOH 
2H2O 
COOH 
Lisinopril dihydrate, l-[n-[(s)-l-Carboxy-3-Phenylpropyl]-L-lysyl]-L-proline 
dlhydrate, belongs to the group of medicines known as ACE inhibitors. It is a lysine 
derivative of analaprilat, which does not require hydrolysis to become active ACE 
inhibitor. Administration of lisinopril blocks the renin angiotensin-aldosterone axis 
and tends to reverse the potassium loss associated with the diuretics. The anti 
hypertensive effects of lisinopril have continued during long term therapy. Abrupt 
withdrawl of lisinopril has not been associated with a rapid increase in blood pressure; 
nor with a significant overshoot of pretreatment of blood pressure. Lisinopril does not 
appear to be bound to other serum proteins. Lisinopril does not undergo metabolism 
and is excreted unchanged entirely in the urine. It is used in the treatment of 
hypertension and heart failure in prophylactic treatment after myocardial infarction 
and in diabetic nephropathy. Lisinopril works by causing blood vessels relax, 
lowering blood pressure and increasing the supply of blood and oxygen to the heart. 
For this reason it is also sometimes used, alongside other medicines, to treat heart 
failure and circulatory problems associated with diabetics. 
45 
LABETALOL HYDROCHLORIDE (C19H24N2O3 • HCI) 
0=C-NH2 
-OH 
• HCI 
Labetalol hydrochloride is chemically known as 5-[l-hydroxy-2-(l-methyl-3-
phenylpropylamino) ethyl salicylamide hydrochloride. Labetalol belongs to the group 
of medicines called P-blockers; it is the first adrenergic antagonist capable of blocking 
both a and P receptors in the heart, lungs and other organs of the body. There are 4 
sterioisomers of labetalol, each of which has a distinct profile of action of subtypes of 
a and P receptors. Labetalol is 5 times more potent in blocking p than a receptors. 
These are often referred to as the 'fight or flight' chemicals as they are responsible for 
the body's reaction to stressful situations. Labetalol is used to treat high blood 
pressure and also to cause controlled low blood pressure during anaesthesia. Beside 
these important pharmacological activities, labetalol therapy exhibits hepatotoxicity 
and renal failure due to overdosage. Fall in blood pressure (both systolic and diastolic) 
is due to tti and Pi blockade as well as P2 agonism (vasodilation). Relatively high 
doses reduce both cardiac output and total peripheral resistance. 
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PERINDOPRIL ERBUMI^fE (CHsaNzOj- C4Hi,N) 
• H2N-C(CH3)3 
0 
Perindopril erbumine is chemically, tertiary-butyl-amine salt of [[2S-1-(R, R) 
2a, 3ap, 7aP]-l-[2-(l-ethoxy carbonyl butyl] amino]-oxopropyl, octahydo-lH indole-
2 carboxylic acid. It is the first member of a new chemical class of a non-peptide 
angiotensin II receptor antagonist used in the treatment of hypertension and 
congestive heart failure. 
S-Perindopril is a pro-drug that is hydrolyzed to the active metabolite perindoprilat. 
The members of this class have the common property of acting as pro-drugs, being 
converted to the active diacid through the metabolic process by liver and intestinal 
enzymes. Its ability to lower blood pressure is comparable to, or better than that of 
other antihypertensive drugs. Recent studies have also proved that S-Perindopril 
suppresses the tumour growth and angiogenesis and can modify clinical features of 
Parkinson's disease. R-Perindopril, which is a by-product produced in the synthesis of 
S-Perindopril, does not have the same activity as the S-enantiomer. 
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Chapter - 2 
Sensitive kinetic spectrophotometric method for 
the determination of captopril in bulk and 
dosage forms 
^ r\ 
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INTRODUCTION 
Captopril, l-[(2S)-3-mercapto-2-methyl propionyl]-L-proline, is a 
sulphahydril containing angiotensin converting enzyme (ACE) inhibitor. It is used in 
the management of hypertension, heart failure and diabetic nephropathy [1]. The 
drug is listed in United States Pharmacopoeia [2], which recommends a HPLC 
method for its assay in bulk and tablet formulations. In order to assure the quantity 
of captopril in dosage forms several methods have been reported which include gas 
chromatography [3, 4], high performance liquid chromatography [5, 6], capillary 
electrophoresis [7 - 9], flow injection analysis [10, 11], titrimetry [12] and atomic 
absorption spectrophotometry [13 - 15]. The content of captopril in pharmaceutical 
preparations and biological fluids has also been determined involving 
electrochemical methods such as potentiometry [16] and amperometry [17]. 
Several spectrophotometric methods have been reported in the literature 
which are based on the reaction of drug with Folin-Ciocalteau reagent [18], 
potassium iodate [19, 20], vanadate [21], bromate-bromide [22], chloramine-T 
[23], tetrazoline blue [24], paUadium(II)chloride [25] and/^-chIoranilic acid [26]. In 
the literature no kinetic spectrophotometric method has been reported for the assay 
of captopril. Therefore, there is a need to develop a kinetic spectrophotometric 
method for the determination of captopril in commercial dosage forms. This chapter 
describes a simple and sensitive kinetic spectrophotometric method for the 
determination of captopril in drug formulations. 
EXPERIMENTAL 
Apparatus 
Spectronic 20 D"^  spectrophotometer (Milton Roy, USA) was used for 
absorbance measurements with matched glass cuvettes. 
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Materials and reagents 
Captopril was kindly provided by Wockhardt India Ltd., and was used as 
received. Aceten tablets (25 mg each, Wockhardt India Ltd.), the only available 
commercial dosage forms, were purchased from local market. All chemicals used 
were of AR grade. 
Standard solution of captopril (0.05%) was prepared in doubly distilled water 
and diluted as necessary. Potassium ferricyanide solution (0.1%) was also prepared 
in doubly distilled water. Ferric chloride solution (0.1%) was prepared by dissolving 
in distilled water, adding 70% HNO3 and finally diluting to the mark with doubly 
distilled water (final concentration of HNO3 0.14%). 
General procedure 
Aliquots (0.2 - 2.2 mL) of 0.005% captopril test solution were pipetted into a 
series of 10 mL volumetric flasks. To each flask, 2.0 mL of 0.1% FeCb solution was 
added followed by 1.0 mL of 0.1% potassium ferricyanide and then diluted with 
doubly distilled water. The contents of the flask were shaken well and immediately 
transferred to the spectrophotometric cell. The absorbance was recorded as a 
function of time at A,max 730 nm against the reagent blank prepared simultaneously. 
The initial rate of the reaction (Ro) at different concentrations was evaluated from 
the slope of the tangent to the absorbance-time curves. The calibration graph was 
constructed by plotting logarithm of the initiai-rate (log Ro) against the logarithm of 
the molar concentration of the drug (log c). 
Procedure for determination of captopril in pharmaceutical preparations 
Ten tablets of Aceten were accurately weighed and powdered. A portion 
equivalent to 50 mg of captopril was extracted with methanol by shaking and filtered 
on Whatmann No. 42 filter paper. The filtrate and washings were evaporated to 
dryness. The residue was dissolved in doubly distilled water and analysed by the 
recommended procedure. 
Determination of Stoichiometry 
The stoichiometry of the reaction was studied by the Bent and French 
method [27]. For this, three sets of experiments were performed. In the first set, the 
concentration of captopril was varied while keeping excess concentrations of FeClj 
(2.07x10"^ M) and potassium ferricyanide (3.04x10"^ M). In the second set, excess 
concentrations of captopril (2.30x10"^ M) and potassium ferricyanide (3.04x10"" M) 
were employed and varying concentration of FeCb. In the last set, concentration of 
potassium ferricyanide was varied and keeping excess concentrations of captopril 
(2.30x10'^ M) and FeCb (2.07x10"^ M). 
Validation 
For evaluation of linearity, the content of captopril was determined at eight 
concentration levels: 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0 and 11.0 |agmL"'. Each 
concentration was analyzed for five times. 
The detection limit [28] was evaluated as: 
LOD = 3.3 — 
h 
where b is the slope and So is the standard deviation of the regression line. 
Three concentrations of reference captopril solution within the linearity 
range were selected: 2.0, 4.0, and 7.0 jigmL"'. Six solutions of each concentration 
were prepared and analysed within one day. This assay was repeated for five 
consecutive days. Recovery experiments were performed using standard addition 
method. The total amount was determined by the proposed procedure. 
Ruggedness 
The ruggedness of the proposed method was determined by assaying the 
captopril content under varying conditions of experimental parameters using 
different batches of the reagent. The operational parameters challenged were: 
2.0 mL of 0.1% FeCb solution (± 0.2 mL); 1.0 mL of 0.1% potassium ferricyanide 
solution (±0.1 mL). Under this condition a sample containing 5.0 ngmL* captopril 
was analysed. 
Interval hypothesis 
For practical purposes, the acceptable bias can be calculated statistically 
[29]. For example, a test method, i.e. initial rate method (method 2) is considered 
acceptable if its true mean value is within ±2.0% of that of the reference method, 
i.e. Sastry's spectrophotometric method (18) (method 1): 
- 0.02 m<(H2-m)< 0.02 m 
this can be written as: 
0.98 <H2/^i< 1.02 
which can be generalised to: 
0L < 2^ / m < 9u 
where 9L and 9u represent the lower and the upper acceptance limits, respectively, 
when H2 is expressed as a proportion of the reference mean ni Statistically, 9L and 
9u are calculated from the relation: 
Z' c 2 , 2 \ 
0 -2 Sit p tab 
( P 2 . 2 A 
V «• ) 
•lOxjX^ + 
. Sttt 
'•I 
2 '^ p^ lab 
X. 0 
where x\ and X2 are estimates of \i.\ and }X2 based on ni and n2 measurements^ 
respectively. Sp is the variance of pooled measurements, t,ab is the tabulated one-
sided /-value, with ni+n2-2 degrees of freedom at the specified level of significance. 
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RESULTS AND DISCUSSION 
Captopril is reducing agent owing to the presence of thiol group (-SH) in its 
structure. In aqueous solution, captopril reduces Fe(III) to Fe(II), but it is oxidised to 
disulphide. Fe(II) immediately reacts with ferricyanide resulting in the formation of 
blue product which absorbs maximally at 730 nm. The absorbance of the coloured 
solution increases with time and hence, a kinetically based method was elaborated to 
assay the captopril in pharmaceutical formulations. However, the following specific 
advantages of the kinetic method can be expected: (/) some experimental steps such 
as filtration and extraction are eliminated before the absorbance measurement; (//) 
selectivity is improved owing to the measurement of the evolution of absorbance 
with time instead of the measuring concrete absorbance value; (///) usually no 
interference is observed due to coloured background of the samples. 
Reaction conditions optimisation 
To study the effect of volume of 0.1% FeCls solution, aliquots equivalent to 
8.0 ngmL"' of drug were pippeted into a series of 10.0 mL volumetric flasks 
followed by varying volume of 0.1% FeCla solution (0.2-2.0 mL) and 1.0 mL of 0.1% 
potassium ferricyanide solution. The absorbance was measured at a fixed time of 24 
minutes because the equilibrium was attained at this time point. The absorbance 
increases with increasing volume of FeCb solution and became constant at 1.2 mL 
(Fig.2.1). The dependence of the volume of 0.1% potassium ferricyanide on the 
formation of blue product was examined by taking a fixed amount of captopril 
(8.0 ngmL"'), 2.0 mL of 0.1% FeCb solution and varying volume of 0.1% potassium 
ferricyanide (0.2-1.6 mL). It was observed that maximum absorbance was obtained 
with 0.9 mL (Fig.2.2). Thus, 2.0 mL of 0.1% FeCb and 1.0 mL of 0.1% potassium 
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Fig. 2.1: Effect of the volume of 0.1% FeCb solution on the intensity of 
colour produced during the reaction. 
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Fig 2.2 Effect of the volume of 0.1% potassium ferricyanide solution on the 
intensity of colour produced during the reaction. 
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ferricyanide were used as optimum volumes for the maximum concentration of 
captopril in calibration graph. 
Stoichiometry 
The stoichiometry of the reaction product was established from the Bent and 
French plots. The plot of log absorbance vs log [Fe(lll)], [K3Fe(CN)6] and 
[Captopril] gave values of the slopes of 1.06, 1.0, and 1.0, respectively, (Fig.2.3 
A,B&C). Hence it is concluded that the reaction proceeds in the molar ratio of 1:1:1. 
The reaction sequence is shown in Scheme 2.1. 
Initial-rate method 
The absorbance vs time curves are shown in Fig. 2.4. The order with respect 
to the Fe(III) was determined by studying the reaction at different initial 
concentration of Fe(III) with fixed captopril concentration. The plot of initial rate 
(AA / At) against initial absorbance was linear passing through the origin suggested 
that the order of the reaction with respect to Fe(III) at the start is one. The order with 
respect to captopril was determined from the measurement of initial rates at several 
concentrations of captopril, keeping a constant concentration of Fe(IIl), which was 
also found to be one. The simple rate expression can be written as: 
rate = k [Fe(lll) Tlcf 
Under the optimised experimental parameters, pseudo-first order condition 
was worked out by taking excess concentrations of FeCls and potassium ferricyanide 
with respect to the initial concentration of captopril. Therefore the above equation is 
reduced to: 
rate= K,Jc]" 
where K^ is the pseudo-first order rate constant, c is the molar concentration 
of captopril. The above equation is written in logarithmic form as: 
67 
-0.4 
-0.6 -
-0.8 
o 
-1.0 
-1.2 
-1.4 
-6.0 
— I — 
-5.8 -5.6 -5.4 
log [Captopril] 
-5.2 -5.0 
Fig 2.3A: Bent and French plot for the molar ratio: log A vs log [captopril] 
with FeCl3=2.07xlO^M and [K3Fe(CN)6]=3.04xlO^M. 
68 
-0.4 
-0.6 
-0.8 
o 
-1.0 
-1.2 
-1.4 
-6.2 -6.0 -5.8 -5.6 -5.4 
log [FeClg] 
-5.2 -5.0 
Fig 2.3B: Bent and French plot for the molar ratio: log A vs log [FeCb] with 
[captoprill=2.03xl0^1Vl and (K3Fe(CN)6l=3.04xlO^M. 
-0.6 
-0.8 
-1.0 
o 
-1.2 -
-1.4 
69 
-1.6 
-5.6 -5.4 -5.2 -50 
log [K3Fe(CN)e] 
-4.8 -46 
Fig 2.3C: Bent and French plot for the molar ratio: log A vs log (K3Fe(CN)6] 
with (captopril]=2.03xlO'^M and FeCl3=2.07xlO"^M 
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log rate = log K^ + « log c = 4.248 + 1.173 log c 
The calibration graph (Fig.2.5) was obtained by plotting the log initial rate 
versus log captopril concentration which showed a linear relationship over the 
concentration range 4.60xl0"^-5.06xl0~^ M (1-llngmL"'). The value of n also 
confirmed that the order of reaction with respect to captopril concentration at the 
initial stage is one. The regression equation, confidence interval of slope and 
intercept of line of regression at 95% confidence level, correlation coefficient, 
variance of calibration line and detection limit were calculated and summarised in 
Table 2.1.The small value of variance of calibration line (2.38x10^) also confirmed 
the negligible scattering of the calibration data points around the line of regression. 
The low value of detection limit (0.04 j^gmL"') pointed towards good sensitivity of 
the proposed procedure. 
The intraday and interday precisions were found to be in the range 0.7 -
1.6% and 0.6 - 1.0%, respectively, (Table 2.2). The percent error was found to vary 
from 0.1 - 1.0%. The results of recovery studies are summarised in Table 2.3. The 
mean percentage recovery ranged from 99.8- 101.4% with relative standard 
deviation values <2.0%. This clearly suggested that there is no interference from 
common excipients present in dosage forms. For evaluation of the method 
ruggedness, two parameters were changed; volume of FeCla and potassium 
ferricyanide solutions. The mean assayed concentration was 4.98 |igmL'' with 
1.02% RSD as a measure of ruggedness. 
The proposed procedure has been successfully applied to the determination 
of captopril in pharmaceutical preparations. The results are summarised in Table 2.4. 
The results obtained by the proposed procedure were compared to those of Sastry's 
spectrophotometric method [18] using point and interval hypotheses. The results 
(Table 2.4) show that the Student's / - and F- values at 95% confidence level are 
less than the theoretical values which confirmed that there is no significant 
/J 
-5.3 -5.2 -5.1 -5.0 -4.9 -4.8 -4.7 -4.6 -4.5 -4.4 -4.3 
Log [Captopril] 
Fig. 2.5: Calibration curve for the determination of captopril by initial rate 
method 
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Table 2.1:Regression data for captopril using initial-rate method 
Parameter Initial-rate method 
Linear dynamic range ( i^gmL"') 1-11 
Regression equation log Ro = 4.248 + 1.173 log c 
Coefficient of correlation (r) 0.9992 
±/Sa^ 2.768x10"^ 
±/Sb^ 2.705x10"^ 
- I Detection limit (ngmL"') 0.04 
Variance of regression line (So^ ) 2.38x 10"^  
/^Sa - confidence interval of the intercept at 95% confidence level. 
^tSb - confidence interval of the slope at 95% confidence level. 
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Table2.2:lntraday and Interday assays 
Concentration (ngmL"') 
Taken 
Intraday assay 
2.0 
4.0 
7.0 
Interday assay 
2.0 
4.0 
7.0 
Found 
2.01 
4.01 
6.93 
2.01 
4.01 
6.98 
Error 
0.50 
0.25 
1.00 
0.50 
0.25 
0.28 
(%) RSD (%)" 
1.1 
0.7 
1.6 
1.0 
0.6 
0.7 
SAE" 
0.01 
0.01 
0.04 
0.01 
0.01 
0.02 
^ Six independent analyses of reference captopril solution. 
'' Standard analytical error. 
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Table2.3: Determination of captopril in pharmaceutical formulations using the 
standard addition technique 
Concentration ((jagmL"') 
Formulation Taken 
Aceten 2.0 
2.0 
7.0 
^ Six independent analyses. 
^ Standard analytical error. 
Added 
2.0 
6.0 
3.0 
Found 
4.05 
7.98 
10.06 
Recovery 
(%) 
101.4 
99.8 
100.6 
RSD 
(%r 
1.8 
1.1 
0.6 
SAE*" 
0.03 
0.03 
0.02 
Table2.4: Point and interval hypotheses: comparison of the proposed method 
with the reference method. 
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Proposed Method Reference 
Method 
[18] 
Formulation 
Aceten 
Recovery 
(%) 
99.3 
RSD 
1.5 
t-
value** 
0.46 
F-
value"* 
2.87 
e^ 
0.98 
0\ 
1.01 
Recovery 
(%) 
99.6 
RSD 
0.9 
^Average of six independent analyses. 
'T'heoretical /- and F- value at 95% confidence level are 1.812 and 5.05, 
respectively. 
"^ In pharmaceutical analysis, a bias on recovery experiments, of ±2% (9L = 0.98 and 
9u = 1.02) is acceptable. 
»n* - '-'Or. 
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difference between the performances of the methods compared. The Canadian 
Health Protection Branch [29] has recommended that a bias, based on recovery 
experiments, of ±2.0% is acceptable for pharmaceutical analysis. The data obtained 
for the analysis of commercial dosage forms show that the true bias is less than 
±2.0%. Thus, the interval hypothesis test has also indicated the acceptable 
performance of the proposed method. 
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Chapter - 3 
Application of 7i-acceptors to the 
spectrophotometric determination of 
lisinopril in commercial dosage forms 
^ f\ 
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INTRODUCTION 
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor wiiich 
chemically known as (N-{N-[(S)-l-carboxy-3-phenyl propyl] L-lysyl}-L-proline 
dihydrate. The drug is used in the treatment of hypertension and prevention of heart 
failure after myocardial infarction [1]. The drug and their tablets are officially listed 
in USP 24 [2] which recommends HPLC method for their quantitation using 
octylsilane column at 50°C and phosphate solution-acetonitrile (96:4 v/v) as mobile 
phase, whereas potentiometric titration has been described in British Pharmacopoeia 
[3] for the assay of lisinopril. 
Several analytical techniques such as HPLC [4-6], LC [7], HPTLC [8], GC 
[9-10], miceller electrokinetic chromatography [11], capillary electrophoresis [12-
13], polarography [14], chemiluminescence [15], radioimmunoassay [16] and 
fluoroimmunoassay [17] have been utilised for the assay of lisinopril in biological 
fluids and/or pharmaceutical preparations. An inspection of the literature reveals that 
most of them are cumbersome or involve the use of expensive equipment and 
reagents. The spectrophotometric methods are the instrumental methods of choice 
and have practical and significant economic advantages over the other methods. In 
the literature several spectrophotometric methods have been reported for the 
determination of lisinopril in pharmaceutical tablets using different reagents 
including 2,4,6-trinitrobenzoic acid [18], l,2-naphthoquinone-4-sulfonic acid [19], 
chloranil and dichlone [20], 7-chloro-4-nitrobenzo-2-oxa-l,3-diazole [21], 
ninhydrin, ascorbic acid, cobalt nitrate-EDTA complex and 2,3-dichloro-5,6-
dicyano-l,4-benzoquinone [22]. Derivative UV spectrophotometric methods have 
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also been utilised for determination of lisinopril in pharmaceutical preparation 
[23-25]. 
This chapter describes two sensitive, fast, simple and economical methods 
for the determination of lisinopril in pure and dosage forms. The methods are based 
on the charge transfer complexation reaction of lisinopril with 
7,7,8,8-tetracyanoquinodimethane (TCNQ) and p-chloranilic acid (pCA). The 
proposed methods are validated statistically. 
EXPERIMENTAL 
Apparatus 
The absorbance was measured on a Spectronic 20D* spectrophotometer 
(Milton Roy, USA) with 1 cm matched glass cells. 
Materials and reagents 
Lisinopril was kindly provided by Unimark Remedies Limited, India, and 
was used as received. Pharmaceutical preparations of lisinopril, such as Zestril-10 
(ICI), Listril (Torrent Pharmaceuticals Ltd), Linvas (Zydus cadilla) and Nivant 
(German Remedies) were purchased from local market. All other reagents used were 
of analytical reagent grade. Solutions of TCNQ (0.1 %; Fluka, Switzerland) and 
/>-chloranilic acid (0.2%; Fluka, Switzerland) were prepared in acetone and 
methanol, respectively. The standard solution of lisinopril (0.25%) was prepared in 
methanol and further diluted according to need. 
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Procedure for determination 
TCNQ Method 
Aliquots of 0.01% lisinopril solution corresponding to 2-26 (igmL"' were 
transferred into a series of 5 mL volumetric flasks. 1.4 mL of 0.1% TCNQ solution 
was added to each flask and diluted to volume with acetone. Absorbance was 
measured after 10 minutes of mixing at 743 nm against reagent blank prepared 
simultaneously. 
pCA Method 
Into a series of 5 mL volumetric flasks, volumes of lisinopril solution 
(0.25%) equivalent to 0.125-1.5 mg of the drug were transferred. To each flask, 
2.0 mL of 0.2% p-chloranilic acid was added and brought upto the volume with 
methanol. The intensity of the colour developed was measured after 3 minutes of 
mixing at 525 nm against the reagent blank prepared similarly omitting the drug. 
The amount of the drug is computed either from calibration graphs or corresponding 
regression equations. 
Analysis of Pharmaceutical Formulations 
Seven tablets (claiming for 10 mg of lisinopril per tablet) were finely 
powdered and dissolved into sufficient volume of methanol. The mixture was stirred 
well and filtered through Whatmann filter paper No.42 and the filtrate was diluted 
with methanol in 50 mL volumetric flask. It was further diluted according to need 
and then analysed following the recommended procedures using TCNQ and/?CA as 
reagents. 
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RESULTS AND DISCUSSION 
Preliminary studies were carried out to establisii the optimum conditions for 
assay of the lisinopril. 
Effect of the reaction time 
The effect of time on the complexation reactions at room temperature was 
examined. It was observed that TCNQ-lisinopril charge transfer complex required 
10 minutes for obtaining maximum and stable absorbance and remained constant 
upto 45 minutes, whereas a stable absorbance for pCA-lisinopril complex was 
obtained after 3 minutes of mixing and remained constant for about a further one 
hour. 
Effect of Solvent 
The effect of solvents such as acetonitrile, acetone, methanol, chloroform 
and 1,4-dioxan on the colour formation was studied. Experimental results indicated 
that acetone was the best solvent for TCNQ-lisinopril system as it gave the 
maximum and stable absorbance. Methanol was a solvent of choice for pCA.-
lisinopril system because intense and stable colour was obtained only after 3 minutes 
of reagent mixing. 
Effect of reagents concentration 
The optimum conditions for the TCNQ and pCA methods were established 
by varying the concentration of reagent at a time and keeping the fixed drug 
concentration and observing the effect produced on the coloured species. 
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To establish the optimum experimental condition for lisinopril-TCNQ charge 
transfer complex, the drug (20 jagmL"') was allowed to react with varying volumes 
of 0.1% TCNQ. The maximum absorbance was obtained with 1.1 mL of the reagent 
(Fig.3.1); further addition caused no change in absorbance. Therefore, a volume of 
1.4 mL was used as an optimum value. 
In thepCA method, the only effective variable is the concentration of/^CA. 
To study the effect of the volume of 0.2% pCA., varying volume of reagent was 
mixed with 250 jigmL"' of drug into a series of 5 mL standard volumetric flask and 
diluted to volume with methanol. It was found that (Fig.3.2) 1.8 mL of reagent 
yielded the highest absorbance; beyond this volume no change in the absorbance 
was observed. A volume of 2.0 mL was, therefore, used in all further measurements. 
TCNQ is a strong 7c-acceptor and forms charge transfer complexes with 
aromatic hydrocarbons, amines and polyhydric phenols. Lisinopril, owing to -NH2 
group, behaves as n-electron donor which readily interacts with TCNQ resulting in 
the formation of bluish-green chromogen having absorption peaks at 743 and 
840 nm (Fig 3.3). The absorption bands are attributed to the formation of TCNQ 
radical anion by complete transfer of electrons from lisinopril molecule to TCNQ in 
polar medium. The absorption band peaking at 743 nm was selected for analytical 
studies. The combining mole ratio between TCNQ and lisinopril in the charge 
transfer complex was evaluated by the method of continuous variation (Fig. 3.4) and 
found to be 1:1. This indicated the presence of one n-electron donating center in the 
lisinopril molecule. On the basis of our experimental findings and literature 
background the formation of TCNQ radical anion is shown in Scheme 3.1. 
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/?-ChloraniIic acid behaving as 7c-acceptor is able to form charge transfer 
complexes with a variety of drugs acting as electron donors. The absorption 
spectrum of pCA in methanol exhibits an absorption band at 440 nm. The addition 
of lisinopril to this solution causes a shift with a new characteristic band at 525 nm 
(Fig. 3.3). The band is due to the formation of/?CA radical anion, which resulted 
owing to the dissociation of/^CA-lisinopril charge transfer complex in methanol. 
The stoichiometry of the reaction product was studied by Job's method of 
continuous variation. The Job's plot (Fig. 3.5) confirmed that the combining mole 
ratio between acceptor and donor is 1:1. On this basis, a tentative reaction 
mechanism has been proposed and given in Scheme 3.2. 
The association constants and apparent molar absorptivities of TCNQ-
lisinopril and /?CA-lisinopril charge transfer complexes have been evaluated using 
Ross and Labes equation [26]. This model is applicable where the acceptor 
concentration is not low enough to be considered negligible with respect to donor 
concentration and hence, the condition is maintained in our systems, 
X X + (1) 
[A] + ID] A, K^, [AMD] e A L^ J^ ' L^J ^A 
where [A] and [D] are molar concentrations of the acceptor and donor, respectively. 
A> and 8x are the absorbance and apparent molar absorptivity of the complex at 
wavelength A.. K is the association constant of the charge transfer complex. 
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•X— is plotted against (Figs. 3.6 & 3.7) which gave a straight [A] + [D] A, [A] + [D] 
line. The intercepts and slopes were calculated and equation (1) is transformed into 
the following equations. 
for TCNQ-lisinopril system 
[A][D] .. i _ , ,^o . . ,^ -8 . . 1 .<no, . , ,A-5 X — = 1.428x10'* X + 6.981x10"' (2) [A] + [D] A, [A] + [D] 
for/?CA-lisinopril system 
M][^] .^_L=jy57^jQ^^ ! + 8.386x10"^ (3) 
[A]HD] A, [A] + [D] 
The association constants and molar absorptivities are 4.890x10^ and 
1.432x10" Lmor'cm"' for TCNQ- lisinopril complex from equation (2); and 47.73 
and 1.192x10'' Lmol"' cm for pCA-lisinopril complex from equation (3), 
respectively. The free energy change was also calculated and found to be -21.76 
KJmol"' and -9.90 KJmol"' for TCNQ- lisinopril and pCA-lisinopril complexes, 
respectively. 
Analytical data 
Under the described experimental conditions of the proposed procedures, the 
plots of absorbance versus concentration were found to show linear relationships 
over the concentration ranges 2-26 ngmL"' and 25-300 figmL'' for TCNQ and pCA 
methods, respectively (Fig.3.8 & 3.9). The regression analyses of these plots using 
the method of least squares were made to evaluate intercept (a), slope (b), 
correlation coefficient (r), confidence limits of intercept (±/Sa) and slope (±/Sb) at 
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95% confidence level. The results are summarised in Table 3.1. The linearity of 
calibration plots was validated by high values of correlation coefficient of regression 
equations and by intercept values, which were close to zero. The high sensitivity of 
the proposed methods was indicated by the values of molar absorptivity, Sandell's 
sensitivity and detection limit. The small values of variance of calibration line have 
also confirmed the negligible scattering of experimental data points from the line of 
best fit for both the procedures. 
The error, Sxo, in the determination of a given concentration of lisinopril has 
been evaluated using the following equation [27]. 
^xo -
1/2 
y I X (4) 
where y and C are the average absorbance and concentration values, respectively, 
for n standard specimen. 
The error, Sxo, is plotted against the concentration of lisinopril (Figs. 3.10 & 3.11) 
for both the methods. It is apparent from the figures that the minimum error is 
observed when determination is made at concentration levels 14 (xgmL"' and 
162 ngmL"' using TCNQ andpCA methods, respectively. The confidence limits at 
the selected level of significance for the determination of unknown concentrations 
have also been established using the equation (5): 
C, ± tp Sxo = Ci ± AC (5) 
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Table 3.1: Optical characteristics and statistical data for the 
regression equation 
Parameters TCNQ method pC\ method 
m^ax (nm) 743 525 
Beer's law limit (^gmL ) 2-26 25-300 
Sandell's sensitivity 3.85x10- 2.78x10 ,-i 
(HgmL"'per 0.001 A) 
Intercept (a) -4.23x10 ,-4 1.02x10" 
Slope (b) 2.62x10- 3.51x10" 
±tS,' 2.051x10" 1.76x10 
-2 
l/Sb" 5.39x10 
,-4 5.88x10" 
Correlation coefficient (r) 0.9999 0.9996 
Variance (So ) .55x10 -7 9.63x10" 
-u Detection limit (^gmL ) 3.85x10- 2.77x10" 
''Confidence interval of the intercept at 95% confidence level. 
''Confidence interval of the intercept at 95% confidence level. 
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The results are shown graphically (Figs. 3.12 & 3.13) in the form of percent 
uncertainty (AC/CxlOO) versus the concentration of lisinopril at 95% and 99% 
confidence levels. From Figs. 3.12 & 3.13 it is also possible to evaluate relative 
uncertainty directly on any concentration over the full range of concentrations 
tested. 
The repeatability of the proposed methods was checked by estimating the 
lisinopril content at three different concentration levels within the Beer's law limit in 
six replicates. The results are presented in Table 3.2. The percent relative standard 
deviation and average recovery were in the range of 0.31-0.52%, 99.94-100.19% 
and 0.37-0.51%, 99.60-100.12% for TCNQ andpCA methods, respectively. 
As an additional demonstration of accuracy, recovery experiments were 
performed by adding a known amount of pure lisinopril to commercial dosage 
forms. The total amount of lisinopril was determined by the proposed procedures. 
The results are summarised in Table 3.3. The good reproducibility was manifested 
by low values of RSD. The values of average recovery obtained by the proposed 
methods have suggested that there is no interference from the common excipients 
present in dosage forms. 
The assay of lisinopril in commercial tablets was performed using the 
proposed procedures and the reference method. The results obtained were compared 
statistically by the student's /-value and variance ratio F-test (Tables 3.4 & 3.5). It is 
evident from these Tables that the calculated /-values and F-values are less than the 
theoretical ones at 95% confidence levels, which showed no significant difference 
with regard to accuracy and precision. 
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The interval hypothesis test has also been performed to compare results of 
proposed methods (TCNQ or pCA) with those of reference method at 95% 
confidence levels. It has been recommended [28] that a bias, based on recovery 
experiments, of ±2% is acceptable for pharmaceutical analysis. The results presented 
in Tables 3.4 & 3.5 show that the true bias of all samples is less than ±2%. The 
interval hypothesis also confirmed that there is no significant difference between the 
methods compared. 
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Chapter - 4 
Determination of labetalol hydrochloride 
in laboratory made tablets by kinetic 
spectrophotometry using potassium 
permanganate as oxidant 
m ^ 
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INTRODUCTION 
Labetalol (LBT) hydrochloride: 5-[I-hydroxy-2- (l-tnethyl-3-
phenylpropylamino) ethyl] salicylamide hydrochloride, is the first adrenergic 
antagonist capable of blocking both a and P receptors. It is a moderately potent 
hypotensive and is specially useful in pheochromocytoma. The drug is used to 
lower blood pressure in myocardial infarction and unstable angina. Beside these 
important pharmacological activities, labetalol therapy exhibits hepatotoxicity and 
renal failure due to overdosage. 
Labetalol is listed in British Pharmacopoeia [1] and United States 
Pharmacopoeia [2], which recommend non-aqueous titration and HPLC methods for 
the assay of its content in pharmaceutical formulations. Several analytical methods 
such as TLC [3-4], HPLC [6-10], LC-MS [11,12], capillary electrophoresis [13-15], 
polarography [16], NMR spectroscopy [17] and spectrofluorimetry [18,19] have 
been reported for the determination of the drug in its pure and commercial dosage 
forms. In addition, some spectrophotometric methods have also been developed for 
the quantitation of the labetalol. Labetalol has been determined in bulk and tablets 
spectrophotometrically [20] based on the reaction of the drug with folin-ciocalteau's 
reagent, 4-aminophenazone, 2,6-dichloroquinone chlorimide and ferric alum with 
Beer's law limit of 8-40, 2.5-15, 5-25, and 50-250 figmL"', respectively. 
Spectrophotometric methods [21] for the assay of labetalol have been described; two 
methods are based on the coupling reaction of labetalol with p-N,N-
dimethylphenylenediamine and 3-methyi-2-benzothiazoiine hydrazone 
hydrochloride in the presence of sodium hypochloride and eerie ammonium sulphate 
as oxidants, respectively and the third method depends on the formation of ion-
association complex of labetalol hydrochloride with Suprachen Violet 3B at pH 1.3. 
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Another extractive spectrophotometric method [22] for assay of labetalol for 
pharmaceutical formulation has been described based on chloroform extractable ion-
association complex of drug with phenazine dye and wool fast blue BL. Belal and 
coworkers [23] have developed two spectrophotometric methods based on the 
phenolic group of the drug. In the first method, labetalol was coupled with 
diazotized benzocaine in the presence of trimethylamine whereas second method 
depends on the coupling of the drug with diazotized p-nitroaniline in presence of 
sodium carbonate. However, some of these methods are tedious and/or time 
consuming. Therefore, a kinetically based spectrophotometric method is presented 
with the advantage of simplicity, reliability and less time of analysis. 
EXPERIIMENTAL 
Apparatus 
The absorbance measurement was made on a spectronic 20 D^ 
spectrophotometer (Milton Roy, USA) with 1 -cm glass cells. 
Material and Reagens 
All the chemicals used were of analytical reagent grade. Doubly distilled water 
was used throughout the experimental work. 
• Labetalol hydrochloride (0.02%; Sigma, USA) was prepared by dissolving 
20 mg in 100 mL doubly distilled water. 
• Potassium permanganate solution (0.1%) was prepared freshly in doubly 
distilled water and its purity was checked titrimetrically 
• Sodium hydroxide solution (IN) was prepared in doubly distilled water and 
kept as stock solution. 
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Procedure for determination 
Aliquots of 2.5 mL KMn04 solution (0.1%) and 1.25 mL of NaOH 
solution (IN) were transferred into a 10 mL volumetric flask. An accurate volume of 
the working solution of labetalol (0.10 - 0.70 mL) was added and diluted to volume 
with doubly distilled water. The mixture was shaken well and immediately 
transferred in spectrophotometric cells. The absorbance was measured at 605 nm as 
a function of time against the reagent blank. The initial rates of the reaction at 
different concentrations were obtained from the slope of the initial tangent to the 
absorbance time curves .The calibration curve was constructed by 
I. plotting the logarithm of initial rate of reaction vs the logarithm of molar 
concentration of labetalol and 
IL the absorbance at a fixed time of 6 minutes vs the initial concentration of 
labetalol. The amount of the drug was computed either from the calibration 
curves or the corresponding regression equations. 
Procedure for pharmaceutical formulations 
Due to the unavailability of the commercial dosage form in the local market, 
tablets A, B & C have been prepared in the laboratory. The laboratory prepared 
dosage forms were further finely grounded and dissolved in water. It was shaken 
well and filtered through tightly packed glass wool bed into 100 mL volumetric 
flask. The whole content was made up to mark with washing and analysed 
following the recommended procedures. 
RESULTS AND DISCUSSION 
It has been reported [24] that labetalol undergoes oxidation with periodate in 
alkaline medium resulting in the formation of 2-hydroxy-5-formyIbenzamide, 
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l-methyl-3-phenylpropylamine and formaldehyde. In this study, alkaline potassium 
permanganate oxidises the labetalol and itself reduces to Mn04" which absorbs 
maximally at 605 nm. On the basis of our experimental findings and literature 
background a tentative reaction sequence is shown in Scheme 4.1. 
Effect of reaction variables 
The various experimental variables affecting the development of the reaction 
products were optimised by changing each variable in turn, while keeping all others 
constant. In the study of optimisation of reaction variables, the absorbance (X-max 
605 nm) was measured at a fixed time of 30 minutes. At room temperature, the rate 
of the reaction increased substantially and hence room temperature was chosen for 
the procedure. The effect of the concentration of potassium permanganate on the 
intensity of the colour developed was studied in the range 3.16x10"^ M-1.90x10'^  M. 
As shown in Fig. 4.1, the absorbance value increased with the increase in the 
concentration of KMn04 and became constant at 1.42x 10"' M. A concentration of 
1.58x10"^  M KMn04 was selected for all further measurements. The influence of 
concentration of NaOH was examined in the range 0.025 M - 0.2 M. It is apparent 
from Fig. 4.2 that increasing the concentration of NaOH would increase the 
absorbance of the reaction product up to 0.1 M; after which further increase in 
concentration resulted in no change in the absorbance. Thus, 0.1 M NaOH was 
chosen as an optimum value for maximum absorbance. 
Analytical Data 
The Initial rate -method 
The initial rates of the reaction were determined by measuring the slope of 
the initial tangent to the absorbance time curves (Fig. 4.3). Under the optimised 
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(LBT: 6.09xlO^M) 
121 
U.D -
0.5-
0.4-
a> 
o 
c 
(0 
•S 0 .3-
o 
v> 
n 
^ 0 . 2 -
0.1 -
0 -
A , 
^—^ 
1 1 
. A 
w 
I 
A 
V 
1 1 
0.00 0.50 1.00 1.50 
Concentration (M) 
2.00 2.50 (XIO-^ ) 
Fig. 4.2: Effect of concentration of NaOH on the absorbance at 605 nm. 
(LBT: 6.09xlO"*M) 
122 
Fig. 4.3: Absorbance vs time graphs for the reaction of labetalol and KMn04 
showing the dependence of the reaction on labetalol concentration . 
Labetalol; (•) 1.218xlO"^M, (o) 2.436xlO"^M, (T) 3.045x10"^M, (V) 
3.654xlO"^M. 
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experimental conditions, the concentrations of KMn04 and NaOH were at least 37 
times and 2900 times higher than the initial concentration of labetalol. Under this 
condition, the pseudo-zero order reaction conditions with respect to the reagents 
concentration were obtained and the rate of the reaction increases with increase i.i 
labetalol concentration. Under pseudo order reaction, the rate equation can be 
written as 
Rate = K^ [labetalol]" 
where Kv^  is the pseudo order rate constant and 'n' is the order of the reaction . The 
reaction can be written in logarithmic form as 
log rate = log K^ + n log [labetalol] 
The regression analysis yielded the following regression equation 
log rate = 2.147 + 0.902 log [labetalol] 
with a correlation coefficient (r) of 0.9969.The value of 'n' suggested that the rate of 
reaction with respect to the labetalol concentration is one. Under the pseudo-first 
order reaction condition, the plot of log rate vs log [labetalol] was linear over the 
concentration range of 2-14 ^gmL~' (Fig. 4.4). The confidence limits for slope and 
intercept were calculated at 95% confidence level and found to be 4.388x10"^ and 
4.168x10", respectively. The limit of detection [25] and variance of the calibration 
line were evaluated and found to be 4.27x10"^ l^gmL"' and 5.293x10"*, respectively. 
The good linearity of the calibration graph and negligible scatter of experimental 
points around the line of the regression are clearly evident by the value of 
correlation coefficient and variance of the calibration line. 
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Log [Labetalol] 
Fig. 4.4: Calibration curve for the determination of labetalol by initial rate 
method 
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Fixed-time method 
In this method, the absorbance of a green coloured solution containing 
varying amount of labetalol was measured at a preselected fixed time. Calibration 
plots of absorbance vs initial concentration of the labetalol were established at a 
fixed time of 2, 4, 6, 8 and 10 minutes. The regression equations, coefficients of 
correlation (r), detection limits and variances of the calibration line were evaluated 
and are given in Table 4.1. It was observed that the most acceptable values of 
correlation coefficient, intercept, detection limit, and variance of the calibration line 
were obtained at a fixed time of 6 min. and therefore a fixed-time of 6 min. was 
adopted for measurement. The calibration graph (Fig. 4.5) was linear over the 
concentration range of 1 - 10 )agmL~'. 
The absolute error, Sc, in the determination of a given concentration of 
labetalol was calculated [26]. Figs. 4.6 & 4.7 show graph of Sc vs concentration of 
labetalol for both the initial rate and fixed-time methods. It is apparent from the 
figures that the error is minimum at 6.8 /igmL"' & 5 j^gmL"' of labetalol for initial 
rate and fixed time methods, respectively. The percent uncertainty (AC/C%) in the 
concentration at 95% and 99% confidence levels for both the methods were 
calculated using the relation 
Ci ±tpSc = C, + AC 
where tp is the student's /-value at the selected level of confidence. 
The percent relative uncertainty was plotted against the concentration 
(Figs. 4.8 & 4.9). The relative uncertainty in the concentration can be calculated at 
any concentration over the full range of concentration tested and therefore, 
confidence limit is established. 
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Table 4.1: Optical and regression characteristics of fixed time method 
Parameters 
Beer's law limit 
(MgmL-') 
Slope (b) 
Intercept (a) 
±/Sa' 
±/Sb' 
Correlation 
Coefficient (r) 
Detection limit 
(HgmL-') 
Variance (SQ^) 
2 min. 
1 -10 
1.439x10"^  
-1.677x10-^ 
1.05x10"^  
1.34x10"^  
0.9957 
0.70 
2.70x10"^ 
4 min. 
1 -10 
1.619x10-^  
5.342x10-^  
1.12x10"^  
1.43x10"^  
0.9961 
0.65 
3.08x10"^ 
6 min. 
1-10 
1.979x10"^  
1.742x10"^  
0.61x10-^ 
0.78x10"^ 
0.9992 
0.29 
0.92x10"^ 
8 min. 
1 -10 
1.931x10'^  
7.205x10'^  
1.01x10-^  
1.30x10"^  
0.9977 
0.50 
2.52x10'^  
10 min. 
1-10 
2.069x10'^ 
9.890x10-^ 
0.83x10"^ 
1.06x10"^  
0.9987 
0.38 
1.70x10"^  
Confidence interval of the intercept at 95 % confidence level. 
''Confidence interval of the intercept at 95 % confidence level. 
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0.18 -
Concentration (ng mL") 
Fig. 4.5: Calibration curve for the determination of labetalol by fixed time 
method 
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Fig. 4.6: Error in the determination of the concentration of labetalol using 
initial rate method. 
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Fig. 4.7: Error in the determination of the concentration of labetalol using 
fixed-time method. 
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Fig. 4.8: Variation of the confidence limit at 95% (•) and 99% (o) confidence 
levels in the form of relative uncertainity in concentration of labetalol 
using initial rate method. 
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Fig. 4.9: Variation of the confidence limit at 95% (•) and 99% (o) confidence 
levels in the form of relative uncertainty in concentration of labetalol 
using fixed-time method. 
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The accuracy and precision was determined by measuring the labetaiol at 
three different concentration levels, each six times, within one day by both initial 
rate and fixed time methods. Intraday data for the precision and accuracy are given 
in Table 4.2 which indicate RSD = 0.61 - 1.69% and SAE = 0.02 - 0.14 for initial 
rate method whereas RSD = 0.68 - 0.82% and SAE = 0.01 - 0.20 for fixed time 
method. The interday accuracy and precision was evaluated at three different 
concentration levels for six consecutive days. The interday RSD and SAE values for 
initial rate and fixed time methods were ranged from 0.57 - 1.26%; 0.68 - 1.47%; 
and 0.01 - 0.03; 0.01 - 0.05, respectively. The intraday and interday data indicated 
the high accuracy and precision of the proposed methods. 
In order to test the reliability of the present method, recovery studies were 
performed. For this, a known amount of pure drug was added to the laboratory made 
tablets at three different concentration levels and total amount was determined by 
the proposed method. Each level was repeated six times. The results (Table 4.3) 
obtained for both the methods showed that the mean recoveries and relative standard 
deviafions were in the range of 99.49 - 100.87% and 0.52 - 1.35%, respectively. 
The initial rate and fixed time methods have been applied to determine the 
labetaiol in laboratory made tablets. The concentration of the drug was computed 
from corresponding regression equations. The results of the proposed method (initial 
rate or fixed-time) were compared with those of the reference method [23] using 
point and interval hypotheses [27]. The result are summarised in Table 4.4, which 
revealed that the calculated / and F values are less than the theoretical ones at 95% 
confidence level confirming no significant difference in the performance of the two 
methods with regard to accuracy and precision. The interval hypothesis has also 
revealed that true bias of all samples is less than ±2.0 %. 
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Table 4.2: Accuracy and precision of within and between run analyses for the 
determination of labetalol hydrochloride by initial rate and fixed-
time methods. 
Nominal 
Concentartion 
C^gmL"') 
Intraday (n=6) 
2.0 
4.0 
6.0 
8.0 
10.0 
12.0 
Interday (n=6) 
2.0 
6.0 
8.0 
10.0 
14.0 
Assayed Concentration (figmL ') 
Initial rate method 
FoundiSD 
1.99±0.03 
3.99±0.06 
5.96±0.09 
8.00±0.05 
9.98±0.07 
11.95±0.07 
1.99±0.03 
5.96±0.06 
8.00±0.05 
9.98±0.07 
13.98±0.08 
RSD 
1.69 
1.45 
1.52 
0.68 
0.76 
0.61 
1.26 
1.11 
0.58 
0.76 
0.58 
SAE 
0.14 
0.02 
0.04 
0.02 
0.03 
0.03 
0.01 
0.03 
0.02 
0.03 
0.03 
1 
CL 
0.07 
0.04 
0.08 
0.11 
0.06 
0.15 
0.05 
0,06 
0.09 
0.06 
0.16 
Fixed-
FoundiSD 
1.99±0.02 
4.02±0.03 
6.02±0.03 
7.99±0.05 
9.91±0.07 
11.97±0.08 
2.00±0.03 
6.01 ±0.05 
7.99±0.06 
9.95±0.07 
13.99±0.10 
time method 
RSD 
1.13 
0.68 
0.82 
0.71 
0.68 
0.65 
1.47 
0.82 
0.79 
0.68 
0.75 
SAE 
0.01 
0.01 
0.20 
0.02 
0.03 
0.03 
0.01 
0.05 
0.02 
0.03 
0.04 
CL 
0.02 
0.05 
0.01 
0.04 
0.14 
0.06 
0.06 
0.010 
0.04 
0.14 
0.08 
SAE= Standard analytical error 
CL= Confidence limit at 95% confidence level 
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Table 4.4: Comparison of results for the determination of labetalol hydrochloride in 
laboratory made tablets 
Formulation 
Tablet A 
Tablet B 
Tablet C 
Recovery (%) 
RSD (%) 
/-value 
F-value 
QL 
eu 
Recovery (%) 
RSD (%) 
/-value 
F-value 
OL 
eu 
Recovery (%) 
RSD (%) 
/-value 
F-value 
OL 
eu 
Proposed Methods 
Initial rate 
99.91 
0.84 
0.69 
1.81 
0.989 
1.004 
100.23 
0.70 
0.14 
1.67 
0.992 
1.009 
100.13 
0.61 
0.83 
2.04 
0.988 
1.004 
Fixed-time 
100.72 
0.94 
1.12 
2.29 
0.996 
1.013 
100.49 
0.97 
0.42 
3.66 
0.993 
1.011 
100.12 
0.93 
0.21 
1.07 
0.989 
1.008 
Reference Method 
[23] 
100.20 
0.62 
100.17 
0.90 
100.13 
0.61 
/-value (v=10) and F-value (v=5, 5) at 95% confidence level are 1.812 and 5.05, respectively. 
In pharmaceutical analysis, a bias, based on recovery experiments of ±2.0% is acceptable 
[eL= 0.98 and eu= 1.02] 
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Chapter - 5 
Optimised and validated initial rate method 
for the determination of perindopril 
erbumine in tablets 
ffti rfti 
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INTRODUCTION 
Perindopril erbumine is a non official drug and is chemically, tert-butyl-
amine salt of [[2S-1-(R, R) 2a, 3ap, 7aP]-l-[2-(l-ethoxy carbonyl butyl] amino]-
oxopropyl, octa-lH indole-2-carboxylic acid. It is an angiotensin converting enzyme 
inhibitor (ACE) [1] used for management of hypertension and congestive heart 
failure. Few analytical procedures have been described for its determination in 
pharmaceutical formulations which include gas chromatography [2], gas 
chromatography mass spectrometry [3], radioimmunoassay [4] and derivatization-
gas chromatography [5]. 
Spectrophotometry still belongs to the most frequently used analytical technique in 
pharmaceutical analysis, which provides practical and significant economic 
advantages over other methods. Abdellatef et. al. have developed two extractive 
spectrophotometric methods for the determination of perindopril, depending upon 
chloroform extractable complex with eosin and copper(ll) [6]. Another method 
involves the chloroform extractable ion association complex of perindopril with 
bromothymol blue at pH 5 [7]. The content of perindopril was determined based on 
its interaction with FeCb in the presence of potassium thiocyanate. UV derivative 
spectrophotometry using zero-crossing method [8] was utilised for the quantification 
of perindopril, where sufficient spectra resolutions of drug and its impurity were 
obtained. 
This chapter describes a kinetic spectrophotometric method for the 
determination of perindopril in commercial tablets. The method is based on the 
reaction of perindopril with l-chloro-2,4-dinitrobenzene (CDNB) in 
dimethylsulphoxide (DMSO) at 40±1''C. The activation parameters such as Ea, AH*, 
AS and AG were calculated. The proposed kinetic method is validated statistically. 
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EXPERIMENTAL 
Apparatus 
All spectrophotometric measurements were made on spectronic 20 D^  
spectrophotometer (Milton Roy, USA). A water bath shaker (NSW 133, New Delhi, 
India) was used to control the heating temperature. 
Materials and reagents 
Perindopril erbumine was kindly supplied as a gift sample by Glenmark 
Pharmaceuticals Ltd., Mumbai, India and used without fiarther purification. DMSO 
and CDNB were purchased from Merck Chemicals, India. 
Commercial tablets of perindopril erbumine such as Coversyl (Serdia 
Pharmaceuticals India Ltd.) and Perigard (Glenmark Pharmaceuticals Ltd., India) 
were purchased from local drug store. 
Standard Solutions 
• l-chloro-2,4-dinitrobenzene solution, 0.2%, was prepared in DMSO. It was 
protected from light and stored in refrigerator. 
• Standard perindopril solution, 0.1%, was prepared in DMSO. 
Proposed Procedure 
Aliquots of standard perindopril solution (0.1%) corresponding to 100 - 700 jig 
were pipetted into a series of 5 mL volumetric flasks. To each flask, 1 mL of 0.2% 
CDNB was added and diluted to volume with DMSO. The contents of the mixture 
were heated on a water bath at 40±1''C. The increase in absorbance at 420 nm was 
recorded against the reagent blank as a function of heating time. The initial rate (Ro) 
of the reaction at different concentrations was evaluated from the slope of the initial 
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tangent to the absorbance-time curves. The calibration graph was constructed by 
plotting initial rate of reaction versus final concentration of perindopril. 
Method validation 
Precision 
Precision of the method was determined by analysing the commercial tablets. 
An amount of the tablet powder equivalent to 100% of the label claim of the 
perindopril was accurately weighed and assayed. The intraday repeatability was 
determined by measuring the perindopril content of the sample solution six times 
within one day at the analytical concentration of 40, 100, and 140 ^gmL''. The 
interday precision was assessed by assaying the sample solution at three 
concentration levels (40, 80 and 140 |xgmL"') on five consecutive days. 
Robustness of the method 
By introducing small changes in the concentration of CDNB and 
temperature, the effects on the results were examined. The volume of 0.2% CDNB 
and temperature were varied as optimum value ±0.2 mL and 40±1°C, respectively. 
Robustness of the method was done at two concentration levels (20 and 100 
ligmL"'). 
Limits of detection and quantitation 
The limits of detection (LOD) and quantitation (LOQ) were calculated using the 
following equations [9]; 
LOD = 3.3 X So/b; LOQ = 10.0 x So/b 
where So and b are the standard deviation and slope of calibration line, respectively. 
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Selectivity 
The selectivity of the method was ascertained by analysing standard 
perindopril in presence of excipients (lactose, magnesium stearate, cellulose and 
talc), impurities and its active metabolite perindoprilat. 
Accuracy 
The samples were spiked with extra 33.33, 100 and 200% of the standard 
perindopril and the mixtures were analysed by the proposed method. The experiment 
was repeated 5 times. This was done to check for the recovery of the drug at 
different levels in the formulations. 
Analysis of marketed formulations 
To determine the content of perindopril in tablets (label claim: 4 mg/tablet) 
the contents of 10 tablets were weighed and finely powdered. A portion of the 
powder equivalent to 40 mg perindopril was stirred with 15 mL DMSO and let stand 
for 10 minutes. The residue was filtered on Whatmann No. 42 filter paper and 
washed with DMSO. The filtrate and washings were diluted to 25 mL with DMSO. 
A suitable volume of this solution was further diluted to give a final concentration of 
1 mgmL"'. An aliquot of the diluted solution was analysed for perindopril content 
following the recommended procedure. 
Reference Method [6] 
Aliquots of 0.1-0.6 mL standard solution of perindopril (1 mgmL"') were transferred 
into a series of 50 mL separating funnels. The volume of each solution was adjusted 
to 10 mL with distilled water, and then 3.0 mL of 0.2% copper(II) sulphate solution 
was added followed by 1.0 mL of 0.1% eosin solution. The complex was extracted 
with 3 x 3 mL portions of chloroform. The solution was shaken for 1 min. each time 
and the chloroform layer was passed through a layer of anhydrous sodium sulphate 
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into a 10 mL volumetric flask. The volume of chloroform layers was made up to 
10 mL and the absorbance was measured at 535 nm against the blank in which drug 
is omitted. The amount of drug in given sample was computed either from 
calibration graph or corresponding regression equation. 
RESULTS AND DISCUSSION 
Perindopril was found to react with CDNB in DMSO medium resulting in 
the formation of coloured product, which absorbed maximally at 420 nm. At room 
temperature, the reaction was slow and more than 1 hour was required to attain the 
maximum absorbance. In order to increase the rate of reaction and decrease the time 
for attaining the equilibrium, the reaction was carried out at 40±1''C. At this 
temperature the intensity of the coloured product increases with time and so a 
kinetically based method was elaborated for determination of perindopril. 
Optimization of variables 
The reaction between perindopril and CDNB was studied at 30±rc, 40±rC 
and 50±1°C in DMSO medium. It was observed that the linear dynamic range for 
determination increases on increasing temperature and become constant at 40±1°C; 
further increase in temperature caused no change in the linear dynamic range. 
Therefore, a temperature of 40±1''C was chosen as an optimum temperature. 
The effect of the volume of 0.2% CDNB on the rate of reaction was studied in the 
range 0.1- 1.3 mL. The rate of reaction or absorbance increases with increase in 
volume of CDNB and becomes constant at 0.8 mL; above this volume no increase in 
the rate of reaction was observed. Thus a volume of 1.0 mL was selected for the 
determination process. 
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Stoichiometry and reaction mechanism 
The molar combining ratio between perindopril and CDNB was evaluated 
using limiting logarithmic method [10] by performing two sets of experiments 
Fig. 5.1. In the first, the concentration of the drug was varied and keeping the CDNB 
concentration constant. In the second, the drug concentration was kept constant and 
varying the CDNB concentration. The slopes of the plots of logarithm of absorbance 
versus logarithm of respective varied molar concentration were calculated and found 
to be 1:1 between perindopril and CDNB. 
Aromatic nitro compounds react with bases resulting in the formation of brightly 
coloured solutions. There are various interactions depending upon the degree to 
which the base participates through its unshared electron pair with the nitro 
compounds [11]. In the present study, perindopril behaves as a base owing to the 
presence of-NH group in its structure. Addition of CDNB to perindopril in DMSO 
yielded the 1-substituted Meisenheimer complex which absorbs maximally at 
420 nm. On the basis of our experimental findings and literature background [12], 
the reaction mechanism is proposed and given in Scheme 5.1. 
Analytical data 
The rate of reaction was found to be dependent on perindopril concentration. 
The initial rate of reaction was obtained from the slope of the initial tangent to the 
absorbance-time curves (Fig.5.2). As can be seen from Fig.5.2 that the initial rate 
increases with increasing perindopril concentration. The kinetic equation for this 
reaction is written as 
Ro = dx / dt =k [Perindopril]" [CDNB]"" (1) 
At [CDNB] > 3.2x 10"^  M, the order of reaction became zero with respect to CDNB 
concentration. The equation (1) is reduced to 
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-4 -3 
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Fig 5.1: Limiting logarithmic plot for molar combining ratio between 
perindopril and CDNB: (o) log A vs log [Drug]; (•) log A vs log [CDNB]. 
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Ro = k [Perindopril]" (2) 
The plot of logarithm of initial rate of reaction versus logarithm of molar 
concentration of perindopril indicated the first order reaction with respect to 
perindopril concentration. The equation (2) is transformed into pseudo first order 
reaction as 
Ro = Kvji [Perindopril] 
where Kv}. is the pseudo first order rate constant. 
The calibration curve obtained by plotting initial rate of reaction versus final 
concentration of perindopril showed a linear relationship over the range 
20 - 140 figmL'' (Fig.5.3). The regression analysis using the method of least squares 
was performed to estimate the slope, intercept and correlation coefficient under 
optimised experimental condifions. The value of LOD, LOQ and variance of the 
calibration line were also calculated and summarised in Table 5.1. 
In order to evaluate the activation parameters, the reaction was studied at 30°C, 40°C 
and 50°C keeping [perindopril] = 2.71x10"* M and [CDNB] = 4.94x10"* M. The 
rate data obtained fi"om pseudo first order kinetics were subjected to fitting in 
Arrhenius Equation. 
K = A e - ^ ^ 
The plot of In k versus 1/T was linear Fig.5.4. and Ea calculated from the slope 
(-Ea/R) was 27.31 KJmof'. The values of AH* and AS* were evaluated using Eyring 
equation 
k = (kbT/h)e^^"'e-^»*'^ 
A plot of In k/T versus 1/T was linear Fig.5.5. The values of AH* and AS* obtained 
from slope (—AH*/R) and intercept (In Ki/h + AS*/R) were 24.69 KJmol"' and 
-134.84 JK'mol"', respectively. The value of AG* was found to be 61.50 KJmol'. 
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Fig 5.4: Arrhenius plot for the reaction between perindopril (2.714x10" M) and 
CDNB (4.937x10-^ M). 
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The intra and interday precisions were evaluated at three concentration levels and 
the results are shown in Table 5.2. It is evident from the Table 5.2 that %RSD was 
found to be less than 1.0% which is considered to be very satisfactory. 
Robustness 
The robustness of the proposed method was evaluated by challenging the 
operational parameters. The operative parameters tested are given as 
• volume of0.2%CDNB (±0.2 mL) 
• Temperature (±1°C) 
Under these conditions, sample solution containing 100 ^gmL"' of perindopril was 
analysed by the proposed method. The low values of RSD (<1.1%) indicated 
robustness of the method. 
Selectivity 
The selectivity of the method was assessed by analysing standard perindopril 
in presence of excipients (lactose, magnesium stearate, cellulose and talc), impurities 
and its active metabolite perindoprilat. It was observed that impurities such as (2S)-
2- [(3S, 5aS, 9aS, 10aS)-3-methyl-l, 4-dioxodecahydropyrazino[ 1, 2-a-]indoIe-
2(lH)-yl] pentanoic acid, ethyl (2S)-2-[(3S, 5aS, 9aS, 10aS)-3-methyl-l, 4-
dioxodecahydropyrazinol[l, 2-a-]indole-2(lH)-yl]pentanoate, (2S)-2-[(3S, 5aS, 9aS, 
10aR)-3-methyi-l, 4-dioxodecahydropyrazinol[l, 2-a-]indoIe-2(lH)-y!]pentanoic 
acid, (2S, 3aS, 7aS)-l-[(2S)-2-[(5RS)-3-cyclohexyl-2, 4-dioxo-5-
propylimidazolidine-1-yl] propanoyl]octahydro-lH-indol-2-carboxylic acid, and 
(2S,3aS,7aS)-l-[(2S)-2-[(5RS)-3-cyclohexyl-2-(cyclohexylimino)-4-oxo-5-
propylimidazolidine-l-yl]propanoyI] octahydro-lH-indol-2-carboxylic acid do not 
interfere with the determination. However other impurities such as (2S,3aS,7aS)-l-
[(2S)-2-[[( 1S)-1 -[(1 -carboxybutyl]amino]propanoyl]octahydro-1 H-indol-2-
carboxylic acid, (2S,3aS,7aS)-l-[(2S)-2-[[(lS)-l-[(l-methylethoxy) carbonyl] 
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butyl]amino]propanoyl]octahydro-lH-indol-2-carboxylic acid, and (2S,3aS,7aS)-l-
[(2S)-2-[[(lR)-l-[(l-ethoxycarbonyl) butyl]amino] propanoyi] octahydro-lH-indol-
2-carboxylic acid interfere with assay procedure. The perindoprilat, the principal 
metabolite of perindopril, also interferes with the determination. However, the 
perindopril can be determined after separation from perindoprilat on Dowex AG 1x2 
column using 0.2 M formic acid as eluent. 
Accuracy 
The proposed method when used for estimation of perindopril from tablets 
after spiking with 33.33, 100 and 200% of additional drug afforded recovery of 
99.82 - 99.93% as listed in Table 5.3. 
The developed method was successfully applied to the assay of perindopril in 
tablets; the results are given in Table 5.4. The same batch tablets were also analysed 
by Abdellatef s spectrophotometric method [6]. This reference method is chosen due 
to its simplicity and sensitivity with good precision and accuracy. The resuhs of the 
proposed method were compared with those of reference method using point and 
interval hypotheses. It is apparent that the calculated /- and F- values are less than 
the theoretical ones at 95% confidence level which showed no significant difference 
between methods compared with regard to accuracy and precision. The interval 
hypothesis test has also confirmed that the true bias of all samples is <i2.0% at 95% 
confidence level. For pharmaceutical analysis, a bias of ±2.0% is acceptable and 
thus the limit of acceptance interval is within 9L = 0.98 and 9u= 1.02. 
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Abstract 
Two simple, rapid and sensitive spectrophotometric methods have been proposed for the determination of lisinopril in pure form and 
pharmaceutical formulations. The methods are based on the charge transfer complexation reaction of the drug with 7,7,8.8.tetracyanoquin-
odimethane (TCNQ) and p-chloranilic acid (pCA) in polar media. The lisinopril-TCNQ and lisinopril-pCA charge transfer complexes dis-
sociate in acetone and methanol, respectively, and yield coloured TCNQ and pCA radical anions which are measured speclrophotometrically 
ul 743 and 525 nm. Under optimised experimental conditions. Beer's law is obeyed in the concentration range of 2-26 and 25-300 jag ml"' 
with molar absorptivity of 1.432 x 10" and 1.192 x 10'' 1 moP' cm"' for TCNQ and pCA methods, respectively. Both the methods have been 
applied to the determination of lisinopril in pharmaceutical dosage forms. Results of analysis are validated statistically. 
© 2005 Elsevier SAS. All rights reserved. 
Keywords: Lisinopril; TCNQ:/)CA: Pharmaceutical formulations; Charge transfer complexes 
1. Introduction 
Lisinopril is an angiotensin-converting enzyme (ACE) 
inhibitor which cheinically known as (W-{A'-[(5)-l-carboxy-
3-phenyl propyl] L-lysyl)-L-proline dihydrate. The drug is 
u.sed in the treatment of hypertension and prevention of heart 
failure after myocardial infarction [ 1 ]. The drug and their tab-
lets are officially listed in USP24 [2j which recommends 
HPLC method for their quantitation using octylsilane col-
umn at 50 °C and phosphate solution/acetonitrile (96:4 v/v) 
as mobile phase, whereas potentiometric titration has been 
described in British Pharmacopoeia [3] for the assay of lisi-
nopril. 
Several analytical techniques such as HPLC [4-6], LC [7], 
HFl'LC [8], GC |9,10], miceller electrokinetic chromatogra-
phy 111 ], capillary electrophoresis j 12,13], polarography [14], 
chemiluminescence [15], radioimmunoassay [16] and fluor-
oimmunoassay [17] have been utilised for the assay of lisi-
* Corresponding author. Tel.: +91 571 270 1620. 
E-mail address: chtl7nr_aniu@yahoo.com (N. Rahman). 
OOI4-827X/$ - sec frx)nt matter © 2005 Elsevier SAS. All rights reserved, 
doi: 10.1016/j.farniac.2005.04.011 
nopril in biological fluids and/or pharmaceutical prepara-
tions. An inspection of the literature reveals that most of thein 
are cumbersome or involve the use of expensive equipment 
and reagents. The spectrophotometric methods are the instru-
mental methods of choice and have practical and significant 
economic advantages over the other methods. In the litera-
ture several spectrophotometric methods have been reported 
for the determination of lisinopril in pharmaceutical tablets 
using different reagents including 2,4,6-trinitrobenzoic acid 
[ 18], 1,2-naphthoquinone-4-sulphonic acid [ 19], chloranil and 
dicholone [20], 7-chloro-4-nitrobenzo-2-oxa-l ,3-diazole [21 ], 
ninhydrin, ascorbic acid, cobalt nitrate-EDTA complex and 
2,3 dichloro, 5,6-dicyano 1,4-benzoquinone [22]. Derivative 
UV spectrophotometric methods have also been utilised for 
determination of lisinopril in pharmaceutical preparations 
[23-25]. 
This paper describes two sensitive, fast, simple and eco-
nomical metliods for the deterinination of lisinopril in pure 
and dosage forms. The methods are based on the charge trans-
fer complexation reaction of lisinopril with 7,7,8,8-
tetracyanoquinodimethane (TCNQ) and p-chloranilic acid 
(pCA). The proposed methods are validated statistically. 
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1. Experimental 
2. /. Apparants 
The absorbaiice was measured on a Spectronic 20D* spec-
tiophutumeter (Milton Roy, USA) with I cm matched glass 
cell. 
2.2. Materials and reagents 
Lisinopril was kindl)' provided by Unimark Remedies Lim-
ited. India, and was used as received. Pharmaceutical prepa-
rations of lisinopril, such as Zestril-IO (ICI), Listril (Torrent 
Pharmaceuticals Ltd.), Linvas (Zydus Cadilla) and Nivant 
(Geiinan Remedies) were purchased from local market. All 
other reagents used were of analytical reagent grade. Solu-
tions of f c N Q (0.1%; Fluka, Switzerland) and pCA (0.2%; 
Fluka, Switzerland) were prepared in acetone and methanol, 
respectively. The standard solution of lisinopril (0.25%) was 
prepared in methanol and further diluted according to need. 
2.3. Procedure for deterniiiwtion 
2.3.1. TCNQ method 
Aliquots of 0.01% lisinopril solution corresponding to 
2-26 ng mP' were transferred into a series of 5 ml volumet-
ric flasks. 1.4 ml of 0.1 % TCNQ solution was added to each 
flask and diluted to volume with acetone. Absorbance was 
measured after 10 min of mixing at 743 nm against reagent 
blank prepared simultaneously. 
2.3.2. pCA method 
Into a series of 5 ml volumetric flasks, volumes of lisino-
pril solution (0.25%) equivalent to 0.125-1.5 mg of the drug 
were transferred. To each flask, 2.0 ml of 0.2% pCA was added 
and brought upto the volume with methanol. The intensity of 
the colour developed was measured after 3 min of mixing at 
525 nm against the reagent blank prepared similarly omitting 
the drug. 
The amount of the drug is computed either from calibra-
tion graphs or corresponding regression equations. 
2.4. Analysis of pharmaceutical formulations 
Seven tablets (claiming for 10 mg of lisinopril per tablet) 
were finely powdered and dis.solved into sufficient volume of 
methanol. The mixture was stirred well and filtered through 
Whatmann filter paper No. 42 and the filtrate was diluted with 
methanol in 50 ml volumetric flask. It was further diluted 
according to need and then analysed following the recom-
mended procedures. 
3. Results and discu.ssion 
Preliminary studies were carried out to establish the opti-
mum conditions for assay of the lisinopril. 
3.1. Effect of the reaction time 
The effect of time on the complexation reactions at room 
temperature was examined. It was observed that TCNQ-
lisinopril charge transfer complex required 10 min for obtain-
ing maximum and stable absorbance and remained constant 
upto 45 min, whereas a stable absorbance for />CA-lisinopril 
complex was obtained after 3 min of mixing and remained 
constant for about a further 1 h. 
3.2. Effect of solvent 
The effect of solvents such as acetonitrile. acetone, metha-
nol, chlorofonn and 1,4-dioxane on the colour formation was 
studied. Experimental results indicated that acetone was the 
best solvent forTCNQ-lisinopril system as it gave the maxi-
mum and stable absorbance. Methanol was a solvent of choice 
for pCA-lisinopril system because intense and stable colour 
was obtained only after 3 min of reagent mixing. 
3.3. Effect of reagents concentration 
The optimum conditions for the TCNQ and pCk methods 
were established by varying the concentration of reagent at a 
time and keeping the fixed drug concentration and observing 
the effect produced on the coloured species. 
To establish the optimum experimental condition for lisi-
nopril-TCNQ charge transfer complex, the drug (20 ^g ml"') 
was allowed to react with varying volumes of 0.1 % TCNQ. 
The maximum absorbance was obtained with 1.1 ml of the 
reagent (Fig. 1); further addition caused no change in absor-
bance. Therefore a volume of 1.4 ml was used as an optimum 
value. 
In thepCA method, the only effective variable is the con-
centration oipCK. To study the effect of the volume of 0.2% 
pCA, varying volume of reagent was mixed with 250 ng ml"' 
of drug into a series of 5 ml standard volumetric flask and 
diluted to volume with methanol. It was found that (Fig. 1) 
8 0.6 
c 
V) 
§ 0.4 
0.0 0.3 0.6 09 1.2 1.6 1.8 2.1 2.4 27 30 
Volume of reagent (ml) 
Fig. 1. Effect of the volume of 0.1% TCNQ (•) and 0.2% /XTA (o) on the 
absorbance of the reaction product. 
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1.8 ml of reagent yielded the highest absoibance; beyond this 
volume no change in the absorbance was observed. A vol-
ume of 2.0 ml was, therefore, used in all further measure-
ments. 
TCNQ is a strong 7i-acceptor and fonns charge transfer 
complexes with aromatic hydrocarbons, amines and polyhy-
dric phenols. Lisinopiil, owing to -NH2 group, behaves as 
n-electron donor which readily interacts with TCNQ result-
ing in the formation of bluish-green chromogen having 
absorption peaks at 743 and 840 nm (Fig. 2). The absorption 
bands are attributed to the fomiation of TCNQ radical anion 
by complete transfer of electrons from lisinopril molecule to 
TCNQ in polar medium 126]. The absorption band peaking 
at 743 nm was selected for analytical studies. The combining 
mole ratio between TCNQ and lisinopril in the charge trans-
fer complex was evaluated by the method of continuous varia-
tion (Fig. 3) and found to be 1:1. This indicated the presence 
of one n-electron donating centre in the lisinopril molecule. 
On the basis of our experimental findings and literature back-
ground the formation of TCNQ radical anion is shown in 
Scheme 1. 
I,,, 
<? 
c o 
O Oo' 
400 500 600 700 800 900 
Wavelength (nm) 
Fig. 2. Absorption spectra of the reaction products of lisinopril with TCNQ 
(o) and pCA (•). 
(0 
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0.2 ' 
0.0 0.2 0.4 0.6 0.8 1.0 
Mole fraction of drug 
Fig. 3. Job's plot for lisinopril-TCNQ complex (o) and lisinopril-pCA com-
plex (•). 
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Scheme 1. 
pCA behaving as 7i-acceptor is able to form charge trans-
fer complexes with a variety of drugs acting as electron 
donors. The absorption spectrum of pCA in methanol exhib-
its an absorption band at 440 nm. The addition of lisinopril to 
this solution causes a shift with a new characteristic band at 
525 nm (Fig. 2). The band is due to the formation of/?CA 
radical anion which resulted owing to the dissociation of 
/jCA-lisinopril charge transfer complex in methanol. The sto-
ichiometry of the reaction product was studied by Job's 
method of continuous variation. The Job's plot (Fig. 3) con-
firmed that the combining mole ratio between acceptor and 
donor is 1:1. On this basis, a tentative reaction mechanism 
has been proposed and given in Scheme 2. 
The association constants and apparent molar absorjitivi-
ties of TCNQ-lisinopril and pCA-lisinopril charge transfer 
complexes have been evaluated using Ross and Labes [271 
equation. This model is applicable where the acceptor con-
centration is not low enough to be considered negligible with 
respect to donor concentration and hence, the condition is 
maintained in our systems 
mm \_ i_ 1 j_ (1) 
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where [A] and [D] are molar concentrations of the acceptor 
and donor, respectively. A; and e^  are the absorbance and ap-
parent molar absorptivity of the complex at wavelength L K 
is the association constant of the charge transfer complex. 
1 1 {A][D] 
•X— is plotted agi ;ainst (Fig. 4) [A]+[D] A. ^ [A]+[D] ^ 
which gave a straight line. The intercepts and slopes were 
calculated and Eq. (1) is transformed into the following equa-
tions. 
For TCNQ-lisinopril system 
•X —=1.428 X 10 X 
[A] + [D] A, {A\ + [D\ 
ForpCA-lisinopril system 
+ 6.981 X 10" (2) 
[A][D] 
IA] + 1D] A, 
X —=1.757 X 10"° X 1 
IA] + (D] 
+ 8.386x10"^ 0) 
The association constants and molar absorptivities are 
4.890 X 10'' and 1.432 x lO" 1 moP' c n r ' for TCNQ-
lisinopril complex from Eq. (2); and 47.73 and 1.192 x 
lO'* 1 moP" cm"' for pCA-lisinopril complex from Eq. (3), 
respectively. The free energy change was also calculated and 
g 1^ / 
+ 
< 
4 -
1 
(1/[A] + (DDxIO" 
Hig. 4. P!(>l oV lAU/Jl/lAJ + \D\ x MA- vs. \I{A\ + 1/)J for evalualioii of 
association constant of lisinopril-'I'CNQ complex (•) and lisiiiopril-pCA 
complex (o). 
found to be -21.76 and -9.90 kJ mop' for TCNQ-lisinopril 
andpCA-lisinopril complexes, respectively. 
3.4. Analytical data 
Under the described experimental conditions of the pro-
posed procedures, the plots of absorbance versus concentra-
tion within the range stated in Table 1 show linear relation-
ships. The regression analyses of these plots using the method 
of least squares were made to evaluate intercept {a), slope 
(b), correlation coefficient (•/), confidence limits of intercept 
(±fSa) and slope {±tS^) at 95% confidence level and variance. 
The results are summarised in Table 1. The linearity of cali-
bration plots was validated by high values of correlation coef-
ficient of regression equations and by intercept values, which 
were close to 0. The high sensitivity of the proposed methods 
was indicated by the values of molar ab.sorptivity, Sandell's 
sensitivity and detection limit. Tlie small values of variance 
have also confirmed the negligible scattering of experimental 
data points from the line of best fit for both the procedures. 
Table 1 
Optical characteristics and statistical data for the regression equation 
Parameters TCNQ 
method 
pCA 
method 
/•.,„, (nm) 74.1 52.'i 
Beer's law limit (pg ml"') 2-26 25-.'i00 
Sandell's sensitivity (|jg mr 'per 0.001 A) 3.85x10"^ 2.78x10"' 
Intercept (a) -4,23 x 10"^  1,02 x 10"-
Slopc(Z)) 2 .62x10- 3.51x10-
±tS„" 2.051x10' 1,76x10-
±r5,,'' 5.39x10-^ 5.88x10' 
Correlation cocfticienl (]•) 0.9999 0,9996 
Variance (S„-) 1,55 x 10"' 9,63 x 10"' 
Detection limit (^g mP') 3,85 xlO~- 2,77x10'' 
" Confidence interval of the intercept at 95% confidence level. 
'' Confidence interval of the slope al 95% confidence level. 
N. Rahman el al. / II Farmaco 60 (20051 605-611 6(W 
O 
< 
Concentration (ng ml') 
Fig. S. Varialion of (he confidence limit al 95% confidence level (o) and 
99'/c confidence level (•) forTCNQ method in the form of percent uncer-
tainty on the concentralioii. 
The error, S^„, in the determination of a given concentra-
tion of iisinopril has been evaluated using the following equa-
tion [28]. 
S , , . ^ 1.1 . ^--''- (4) 
where y and C are the average absorbance and concentration 
values, respectively, for n standard specimen. 
The minimum error is observed when determination is 
made at concentration levels 14 and 162 |ig ml"' using TCNQ 
and pCA methods, respectively. The confidence limits at the 
selected level of significance for the determination of un-
known concentrations have also been established using the 
Eq. (5). 
The results are shown graphically (Figs. 5 and 6) in the 
form of percent uncertainty (AC/C x 100) versus the concen-
tration of Iisinopril at 95% and 99% confidence levels. From 
Figs. .5 and 6 it is also possible to evaluate relative uncer-
tainty directly on any concentration over the full range of con-
centrations tested. 
The repeatability of the proposed methods was checked 
by estimating the Iisinopril content at three different concen-
tration levels within the Beer's law limit in six replicates. 
Tabic 2 
Test of precision and accuracy of the propo-sed methods 
y 20 
o 
<! 
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Fig. 6. Variation of the confidence limit at 95% confidence level (o) and 
99% confidence level (•) for/)CA method in the form of percent uncertainty 
on the concentration. 
The results are presented in Table 2. The percent relative stan-
dard deviation and average recovery were in the range of 0.31-
0.52%, 99.94-100,19% and 0.37-0.51 %, 99.60-100.12% for 
TCNQ and pCA methods, respectively. 
As an additional demonstration of accuracy, recovery 
experiments were performed by adding a known amount of 
pure Iisinopril to commercial dosage forms. The total amount 
of Iisinopril was detennined by the proposed procedures. The 
results are summarised in Table 3. The good reproducibility 
was manifested by low values of R.S.D. as evident from 
Table 3. The values of average recovery obtained by the pro-
posed methods have suggested that there is no interference 
from the common excipients present in dosage forms. 
The assay of Iisinopril in commercial tablets was per-
formed using the proposed procedures and the reference 
method. The results obtained were compared statistically by 
the Student's /-value and variance ratio F-test (Tables 4 and 
5). It is evident from the.se Tables that the calculated /-values 
and F-values are less than the theoretical ones at 95% confi-
dence levels which showed no significant difference with 
regard to accuracy and precision. 
The interval hypothesis test has also been performed to 
compare results of proposed methods (TCNQ or pCA) with 
those of reference method at 95% confidence level (Table 6). 
It has been recommended [29] that a bias, based on recovery 
experiments, of ± 2% is acceptable for pharmaceutical analy-
sis. The results presented in Table 6 show that the true bias of 
all samples is less than ± 2%. The interval hypothesis also 
Proposed method Amount taken (pg mP ) Amount found ± S.D. (jjg ml ') Recovery (%) R.S.D. (%) SAE CL 
TCNQ 
pCA 
4 
12 
24 
50 
1.50 
250 
4.01 ± 0.02 
12.01 ±0.06 
23.98 ± 0.08 
49.80 ± 0.26 
150.18 ±0.56 
249.76 ± 0.96 
100.19 
100.08 
99.94 
99.61 
100.12 
99.90 
0.52 
0.49 
0.31 
0.51 
0.37 
0.38 
0.008 
0.024 
0.030 
0.408 
0.228 
0392 
0.017 
0.048 
0.062 
0.822 
0.461 
0.790 
SAE = standard analytical error; CL = confidence limit al 95% confidence level. 
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Table 3 
Assay results of lisinopril in 
I'oniuihilion 
5^stril-!0 
Lislril-10 
Liiivas-IO 
Nivant-IO 
Taken 
2 
2 
20 
2 
2 
20 
2 
2 
20 
2 
2 
20 
pharmaceutical preparation by proposi: 
Ann>unl \ 
Added 
T 
10 
4 
2 
to 
4 
2 
10 
4 
2 
10 
4 
TCNQ method 
p j ml"'» 
Found ± S.D. 
3.976 ±0.019 
11.991 ±0.040 
23.985 ± 0.075 
3.963 ± 0.019 
11.997 + 0.046 
23.997 ± 0.077 
4.001 ±0.019 
12.016 ±0.05 
24.01 ±0.08 
4.014 ±0.019 
12.023 ±0.046 
23.978 ± 0.086 
Recovery 
d^ proced 
SAE 
( p g m r ' ) ± R . S . D 
[%) 
100.03 ±0.49 
100.13 ±0.42 
100.04 ±0.34 
99.08 ± 0.49 
99.97 ± 0.38 
99.99 ± 0.32 
100.03 ±0.49 
100.13 ±0.42 
100.04 ±0.34 
100.35 + 0.49 
ICX).19 + 0.38 
99.91 ±0.36 
0.008 
0.016 
0.030 
0.008 
0.019 
0.032 
0.008 
0.U20 
0.033 
0.008 
0.019 
0.035 
ures usii 
CL 
0.017 
0.033 
0.062 
0.017 
0.038 
0.064 
0.017 
0.042 
0.067 
0.017 
0.038 
0.070 
ng standard addition techniques 
Taken 
25 
50 
150 
25 
50 
150 
25 
50 
150 
25 
50 
150 
pCt\ method 
.Amount t^g ml ' ' ) 
Added 
25 
UX) 
100 
25 
IfX) 
1(K) 
25 
100 
100 
25 
100 
100 
round ± S.D. 
50.098 ± 0.204 
149.780 + 0.419 
249.782 ± 0.735 
49.908 ± 0.335 
1.50.017 ±0.509 
249.88 ± 0.779 
50,086 ± 0.204 
150.077 ±0.627 
250.066 ±0.713 
49.99 ±0.168 
149.97 ±0.522 
249.83 ± 0.8 
Recovery 
(pi; Tnr ' )± 
R.S.D. (%) 
100.19 + 0.40 
99.85 ± 0.28 
99.91 ±0.29 
99.81 ±0.67 
100.01 ±0.34 
99.95 + 0.31 
100.17 + 0.40 
100.05 + 0.42 
100.02 + 0.28 
99.98 ± 0.33 
99.98 ± 0,35 
99.93 ± 0.32 
SAE 
0.083 
0.171 
0.300 
0.137 
0.208 
0.318 
0.083 
0.256 
0.291 
0.06S 
0.213 
0.326 
CL 
0.168 
0..345 
0.859 
0.276 
0.419 
0.640 
0.168 
0.516 
0.586 
0.138 
0.429 
0.658 
Table 4 
Comparison of the TCNQ method with the reference method 
Kormulation 
/^stril-10 
Listril-10 
Linvas-10 
Nivant-10 
TCNQ Method 
Recovery" 
100.13 
100.13 
100.25 
100.21 
C -^J S.D. 
0.076 
0.072 
0,090 
0,052 
SAH 
0,031 
0.029 
0.037 
0,021 
CL 
0,063 
0,059 
0,074 
0,043 
f-value'' 
0.525 
0.470 
0.560 
0.742 
/••-value " 
1.147 
1.382 
1.723 
1.160 
Reference 
Recovery 
99,99 
99.99 
99.92 
100.06 
method |211 
(%) S.D. 
0.071 
0.085 
0.069 
0.056 
SAK 
0.029 
0.034 
0,028 
0,023 
CL 
0.058 
0.070 
0.056 
0.046 
"Six independent analyses. 
''Theoretical I- and f-values at 95% confidence level is 1.812 and 5.05, respectively. 
Table 5 
Comparison of the /)CA method with the reference method 
/)CA method Reference iiiethcxl 120J 
Formulation Recovery * (%) S.D. SAE CL /-value" F-value" Recovery (%) S.D, SAE CL 
Zestril-IO 
Listril-lO 
Lii\vas-10 
Nivant-IO 
99,75 
100,04 
99.75 
100,04 
0.690 0.281 0.567 0.357 
0.560 0.228 0.461 0.905 
0.690 0.281 0.568 0.624 
0,588 0,240 0,484 0,764 
1.697 
1,481 
1,189 
1,155 
99,88 
99,74 
99,99 
99,77 
0,529 
0.681 
0.632 
0,632 
0,216 
0,278 
0,258 
0,258 
0.436 
0.531 
0.520 
0.520 
" Six independent analyses, 
''Theoretical r- and f-values al 95% confidence level is 1,812 and 5,05, respectively. 
Table 6 
Internal hypothesis: comparison of the results of the proposed methods with 
the reference method 
Formulation TCNQ method pCA method 
ing necessary research facilities. Thanks are also extended to 
M/s Unimark Remedies Limited, India, for providing a gift 
sample of pure lisinopril. 
Zestril-lO 
Lislril-10 
Linvas-10 
Nivant-IO 
Lower liiiiit 
("J" 
0.9965 
0.9961 
0.9954 
0,9979 
Upper limit 
(o,r 
1.006 
1.006 
1.008 
1,005 
Lower limit 
(o,r 
0,992 
0.997 
0.9907 
0.9963 
Upper 
(Ou)" 
1.005 
1.009 
1,004 
1.009 
limit 
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Optimized and Validated Initial-Rate Method for the Determination of 
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A simple and sensitive kinetic spectrophotometric method for the determination of perindopril in pharma-
ceutical preparations is described. The method is based on the interaction of drug with l-chIoro-2,4-dinitroben-
zene (CDNB) in dimethylsulfoxide (DMSO) at 40±I °C. The reaction is followed spectrophotometrically by mea-
suring the rate of change of the absorbance at 420 nm. Under the optimized experimental conditions, the calibra-
tion curve showed a linear relationship over the concentration range of 20—140^g/ml. The activation parameter 
such as £ , , A//*, A^* and A^* for this reaction were calculated and found to be 27J1 kJ/mol, 24.69 kJ/mol, 
— 158.84 J/K/mol and 61.50 kJ/mol, respectively. The method has been successfully applied to the determination 
of perindopril in commercial dosage forms. Statistical comparison of the results with the Abdellatef's spec-
trophotometric method" shows excellent agreement and indicates no significant difference between the methods 
compared in terms of accuracy and precision. 
Key words perindopril; 1-chloro-2,4-dinitrobenzene; kinetic spectrophotometry; meisenheimer complex 
Perindopril erbumine is a non official drug and is chemi-
cally, /ert-butyl-amine salt of [[2S-HR,R)2a,'iap,lap\-\-
[2-(l-ethoxy carbonyl butyl]amino]-oxopropyl, octa-1// in-
dole-2 carboxylic acid. It is an angiotensin converting en-
zyme inhibitor (ACE)" used for management of hyperten-
sion and congestive heart failure. Few analytical procedures 
have been described for its determination in pharmaceutical 
formulations which include gas chromatography,^ * gas chro-
matography mass spectrometry,'' radioimmunoassay,'*' and 
derivatization-gas chromatography.'' 
Spectrophotometry still belongs to the most frequently 
used analytical technique in pharmaceutical analysis, which 
provides practical and significant economic advantages over 
the other methods. Abdellatef et al. have developed two ex-
tractive spectrophotometric methods for the determination of 
perindopril, depending upon chloroform extractable complex 
with eosin and copper(II).*' Another method involves the 
chloroform extractable ion association complex of perindo-
pril with bromothymol blue at pH 5." The content of 
perindopril was determined based on its interaction with 
FeClj in the presence of potassium thiocyanate. UV deriva-
tive spectrophotometry using zero-crossing method*' was uti-
lized for the quantification of perindopril, where sufficient 
spectra resolutions of drug and its impurity were obtained. 
This paper describes a kinetic spectrophotometric method 
for the determination of perindopril in commercial tablets. 
The method is based on the reaction of perindopril with 
CDNB in DMSO at 40 °C. The activation parameters such as 
activation energy {E^, AH*, AS* and AG* were calculated. 
The proposed kinetic method is validated statistically. 
Experimental 
Apparatus All spectrophotometric measurements were made on spec-
tronic 20 D* spectrophotometer (Milton Roy, U.S.A.). A water bath shaker 
(NSW 133, New Delhi, India) was used to control the heating temperature. 
Materials and Reagents Perindopril erbumine was kindly supplied as a 
gift sample by Glenmark Pharmaceuticals Ltd., Mumbai, India and used 
without further purification. DMSO and CDNB were purchased from Merck 
Chemicals, India. 
Commercial tablets of perindopril erbumine such as Coversyl (Serdia 
Pharmaceuticals (India) Ltd. and Perigard (Glenmark Pharmaceuticals Ltd., 
India) were purchased from local drug store. 
Standard Solutions 1-Chloro-2,4-dinitrobenzene (CDNB) solution, 
0.2%, was prepared in DMSO. It was protected from light and stored in re-
frigerator. 
Standard perindopril solution, 0.1%, was prepared in DMSO. 
Proposed Procedure Aliquots of standard perindopril solution (0.1%) 
corresponding to 100—700/tg were pipetted into a series of 5 ml volumetric 
flask. To each flask 1 ml of 0.2% CDNB was added and diluted to volume 
with DMSO. The contents of the mixture were heated on a water bath at 
40±1 °C. The increase in absorbance at 420 nm was recorded against the 
reagent blank as a function of heating time. The initial rate (SQ) of the reac-
tion at different concentration was evaluated from the slope of the initial tan-
gent to the absorbance-time curves. The calibration graph was constructed 
by plotting initial rate of reaction versus final concentration of perindopril. 
Method Validation. Precision Precision of the method was determined 
by analyzing the commercial tablets. An amount of the tablet powder equiv-
alent to 100% of the label claim of the perindopril was accurately weighed 
and assayed. The intiaday repeatability was determined by measuring the 
perindopril content of the sample solution six times within one day at the an-
alytical concentration of 40, 100, and 140/ig/ml. The interday precision was 
assessed by assaying the sample solution at three concentration levels (40, 
80, I40fig/m\) on five consecutive days. 
Robustness of the Method By introducing small changes in the con-
centration of CDNB and temperature, the effects on the results were exam-
ined. The volume of 0.2% CDNB and temperature were varied as optimum 
value ±0.2 ml and 40± 1 °C, respectively. Robustness of the method was 
done at two concentration levels (20, 100/ig/ml). 
Limit of Detection and Limit of Quantitation The limits of detection 
(LOD) and quantitation (LOQ) were calculated using the following equa-
tions'' 
LOD=3.3X5yA; LOQ=10.0XS^6 
where Sj and b are the standard deviation and slope of calibration line. 
Selectivity The selectivity of the method was ascertained by analyzing 
standard perindopril in presence of excipients (lactose, magnesium stearate, 
cellulose and talc), impurities and its active metabolite perindoprilat. 
Accuracy The samples were spiked with extra 33.33, 100 and 200% of 
the standard perindopril and the mixtures were analyzed by the proposed 
method. The experiment was repeated 5 times. This was done to check for 
the recovery of the drug at diflFerent levels in the formulations. 
Analysis of Marketed Formulations To determine the content of 
perindopril in tablets (label claim: 4mg/tablet) the contents of 10 tablets 
were weighed and finely powdered. A portion of the powder equivalent to 
40 mg perindopril was stirred with 15 ml DMSO and let stand for lOmin. 
The residue was filtered on Whatman No. 42 filter paper and washed with 
DMSO. The filtrate and washings were diluted to 25 ml with DMSO. A suit-
able volume of this solution was fiirther diluted to give a final concentration 
of 1 mg/ml. An aliquot of the diluted solution was analyzed for perindopril 
content following the recommended procedure. 
* To whom correspondence should be addressed, e-mail: chtl7nr_amu@yahoo.com © 2006 Pharmaceutical Society of Japan 
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Kefcrence Method" Aliquots of 0.1—0.6 ml standard solution of 
pcrindopril (1 mg/ml) were transferred into a series of 50ml separating fun-
nels. The volume of each solution was adjusted to 10 ml with distilled water, 
and then 3.0 ml of 0.2% copper(ll) sulphate solution was added followed by 
1.0 ml of 0.1% eosin solution. The complex was extracted with 3X3 ml por-
tions of chloroform. The solution was shaken for 1 min each time and the 
chloroform layer was passed through a layer of anhydrous sodium sulphate 
into a 10 ml volumetric flask. The volume of chloroform layers was made 
upto 10 ml and the absorbance was measured at 535 nm against the blank in 
which drug is omitted. The amount of drug in given sample was computed 
either from calibration graph or corresponding iicgression equation. 
Results and Discussion 
Perindopril was found to react with CDNB in DMSO 
medium resulting in the formation of coloured product, 
which absorbed maximally at 420 nm. At room temperature, 
the reaction was slow and more than 1 h was required to at-
tain the maximum absorbance. In order to increase the rate of 
reaction and decrease the time for attaining the equilibrium, 
the reaction was carried out at 40 °C. At this temperature the 
intensity of the coloured product increases with time and so a 
kinetically based method was elaborated for determination of 
perindopril. 
Optimization of Variables The reaction between 
perindopril and CDNB was studied at 30 °C, 40 °C and 50 °C 
in DMSO medium. It was observed that the linear dynamic 
range for determination increases on increasing temperature 
and become constant at 40 °C; fiirther increase in tempera-
ture caused no change in the linear dynamic range. There-
fore, a temperature of 40°C was chosen as an optimum tem-
perature. 
The effect of the concentration of CDNB on the rate of re-
action was studied in the range 4.0X10"^—4.4X10~^M. The 
rate of reaction or absorbance increases with increase in con-
centration of CDNB and becomes constant at 3.2X10~^M; 
above this concentration no increase in the rate of reaction 
was observed. Thus a concentration of 4.0X10"^ M was se-
lected for the determination process. 
Stoichiometry and Reaction Mechanism The molar 
combining ratio between perindopril and CDNB was evalu-
ated using limiting logarithmic method"" by performing two 
sets of experiments Fig. 1. In the first, the concentration of 
the drug was varied and keeping the CDNB concentration 
constant. In the second, the drug concentration was kept con-
stant and varying the CDNB concentration. The slopes of the 
plots of logarithm of absorbance versus logarithm of respec-
tive varied molar concentration were calculated and found to 
be 1:1 between perindopril and CDNB. 
Aromatic nitro compounds react with bases resulting in 
the formation of brightly coloured solutions. There are vari-
ous interactions depending upon the degree to which the base 
participate through its unshared electron pair with the nitro 
compounds.'" In the present study, perindopril behaves as a 
base owing to the presence of-NH group in its structure. 
Addition of CDNB to perindopril in DMSO yielded the 1-
substituted Meisenheimer complex which absorbs maximally 
at 420 nm. On the basis of our experimental findings and lit-
erature background,'^' the reaction mechanism is proposed 
and given in Chart 1. 
Analytical Data The rate of reaction was found to be 
dependent on perindopril concentration. The initial rate of re-
action was obtained from the slope of the initial tangent to 
the absorbance-time curve Fig. 2. As can be seen from Fig. 2 
§ 
? 
log Molar concentration 
Fig. 1. Limitting Logarithmic Plot for Molar Combining Ratio between 
Perindopril and CDNB 
O, log A vs. log [Drug]; • , log A vs. log [CDNB]. 
CH]—S CHj . 
S H 
DMSO Perindopril 
Meisenheimer complex 
Chart 1 
Heating time (minutes) 
Fig. 2. Absorbance vs. Heating Time Graph for the Reaction between 
PeHndopril and CDNB, Showing the Dependence of the Reaction on 
Perindopril Concentration 
i», 5.428X10 'M;O,16.283X10"*M; •,21.711X10 'M;V, 32.567X10 'M. 
that the initial rate increases with increasing perindopril con-
centration. The kinetic equation for this reaction is written as 
/Jo=<faW'=/^ [Perindopril]" [CDNB]" (I) 
At [CDNB]>3.2X10'^M, the order of reaction became zero 
with respect to CDNB concentration. The Eq. 1 is reduced to 
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R^=K [Perindopril]" (2) 
The plot of logarithm of initial rate of reaction versus loga-
rithm of molar concentration of perindopril indicated the first 
order reaction with respect to perindopril concentration. The 
Eq. 2 is transformed into pseudo first order reaction as 
/?„ = A'.^[Perindopril] 
where K^ is the pseudo first order rate constant. 
The calibration curve obtained by plotting initial rate of 
reaction versus final concentration of perindopril showed a 
linear relationship over the range 20—140//g/ml. The re-
gression analysis using the method of least square was per-
formed to estimate the slope, intercept and correlation coeffi-
cient under optimized experimental conditions. The value of 
LOD, LOQ and variance were also calculated and summa-
rized in Table 1. 
In order to evaluate the activation parameters, the re-
action was studied at 30 °C, 40 °C and 50 °C keeping 
[perindopril]=2.71XlO-'M and [CDNB]=4.94X10" ' 'M. 
The rate data obtained from pseudo first order kinetics were 
subjected to fitting in Arrhenius Equation. 
The plot of In/t versus \IT was linear Fig. 3. and E^ calcu-
lated firom the slope {-EJR) was 27.31 kJ/mol. The values of 
A//* and A ^ were evaluated using Eyring equation 
*r=(/t^77A)e'^«e-'^""" 
A plot of \nklT versus \IT was linear Fig. 4. The values of 
A//* and AS* obtained from slope {-AH*/R) and intercept 
(\nK^,/h+AS*/R) were 24.69 kJ/mol and -134.84 J/K/mol, 
respectively. The value of AG* was found to be 61.50 kJ/mol. 
Table 1. Optical and Regression Characteristics of Initial Rate Method 
Parameters Data 
Linear dynamic range (//g/ml) 
Regression equation 
S. 
its, 
S, 
±tS, 
Correlation coefficient (r) 
LODOig/ml) 
LOQO/g/ml) 
Variance (S,^ ) 
20—140 
«„= 1.90X 10''+0.7797 [Perindopril] 
4.41X10"' 
8.57X10 ' 
1.54X10"^ 
2.98X10"^ 
0.9990 
6.33 
19.20 
1.65X0'" 
The intra and interday precision were evaluated at three 
concentration levels and the results are shown in Table 2. It is 
evident from the Table 2 that %RSD was found to be less 
than 1.0% which is considered to be very satisfactory. 
Robustness The robustness of the proposed method was 
evaluated by challenging the operational parameters. The op-
erative parameters tested are given as 
• volume of 0.2% CDNB (±0.2 ml) 
• temperature (± 1 °C) 
Under these conditions, sample solution containing 100/jg/ 
ml of perindopril was analyzed by the proposed method. 
The low values of RSD (<1.1%) indicated robustness of the 
method. 
Selectivity The selectivity of the method was assessed 
by determining the perindopril content in the presence of ex-
3.35 3,30 3.25 3.20 3.15 3.10 3 05 
(l /T) Kelvin 
Fig. 3. Arrhenius Plot for the Reaction between Perindopril (2.714X 
10" M) and CDNB (4.937X 10" M) 
320 
^^rT) Kelvin 
±/5',=confidence limit for intercept. ±/5^=confidence limit for slope. 
Fig. 4. Eyring Plot for the Reaction between Perindopril (2.714X10 ''M) 
and CDNB (4.937 X10" M) 
Table 2. Evaluation of Accuracy and Precision of the Proposed Method 
Intraday assay amount (pg/m\) 
Taken 
40 
100 
140 
Interday assay amount (/ig/ml) 
40 
80 
140 
Found ±S.D. 
39.60+0.34 
100.91 ±0.98 
139.97±0.% 
39.74±0.34 
80.12 ±0.74 
140.01 ±0.92 
Recovery°'±RSD 
(%) 
98.99+0.86 
100.91+0.97 
99.98+0.69 
99.36+0.85 
100.14+0.92 
100.01+0.66 
SAE"' 
0.139 
0.400 
0.393 
0.408 
0.301 
0.374 
CL" 
0.280 
0.808 
0.792 
0.822 
0.606 
0.754 
a) Average ofsix independent analysis, b) Standard analytical error, c) Confidence limit at 95% confidence level. 
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cipients such as lactose, magnesium stearate, cellulose and 
talc, varying amount of impurities and perindoprilat. It was 
observed that impurities such as (25)-2-[(35,5a5,9a5,10a5)-
3-methyl-1,4-dioxodecahydropyrazino[ 1,2-a-]indole-2( 1//)-
yI]pentanoic acid, ethyl (25)-2-[(35,5a5,9a5,10aS)-3-meth-
yl-1,4-dioxodecahydropyrazinol[ 1,2-a-]indole-2( 1 H)-yl]-
pentanoate, (25)-2-[(35',5a5,9aS', 1 Oa;?)-3-methyl-1,4-dioxo-
decahydropyrazinol[l,2-a-]indole-2(l/f)-yl]pentanoic acid, 
(ISMSJaS)-1 -[(25')-2-[(5;?5)-3-cyclohexyl-2,4-dioxo-5-
propylimidazo!idine-l-yl]propanoyl]octahydro-l//-indol-2-
carboxylic acid, and (25,3a5',7a5^-l-[(25)-2-[(5/?5)-3-cyclo-
hexyl-2-(cyclohexylimino)-4-oxo-5-propylimidazolidine-l-
yl]propanoyl]octahydro-l//-indol-2-carboxylic acid do not 
interfere with the determination. However other impurities 
such as (25,3a5,7a5)-l-[(25)-2-[[(15)-l-[(l-carboxybutyl]-
amino]propanoyl]octahydro-l//-indol-2-carboxyIic acid, 
(25,3aS,7a5)-1 -[(2S)-2-[[( 15)-1 -[(1 -methylethoxy)caibonyl]-
butyl]amino]propanoyl]octahydro-1 //-indol-2-carboxylic 
acid, and (25,3a5,7a5)-l-[(25)-2-[[(l/?)-l-[(l-ethoxycar-
bonyl)butyl]amino]propanoyl]octahydro-l//-indol-2-car-
boxylic acid interfere with assay procedure. The perindopri-
lat, the principal metabolite of perindopril, also interferes 
with the determination. However, the perindopril can be de-
termined after separation from perindoprilat on Dowex 
AGl X2 column using 0.2 M formic acid as eluent. 
Accuracy The proposed method when used for estima-
tion of perindopril from tablets after spiking with 33.33, 100 
and 200% of additional drug afforded recovery of 99.82— 
99.93% as listed in Table 3. 
Table 3. Accuracy and Recovery 
Excess of drug added Recovery' ± RSD 
to the analyte (%) (%) SAE" CL" 
0 
33.33 
100 
200 
99.93 ±0.86 
99.09±1.01 
99.84+1.01 
99.82±0.72 
0.422 
0.163 
0.330 
0.352 
0.851 
0.329 
0.665 
0.710 
8) 
9) 
10) 
11) 
a) Average of six independent analysis, 
dence limit at 95% confidence level. 
b) Standard analytical error, c) Confi- '2) 
The developed method was successfully applied to the 
assay of perindopril in tablets; the results are given in Table 
4. The same batch tablets were also analysed by Abdellatef's 
spectrophotometric method.*' This reference method is cho-
sen due to its simplicity and sensitivity with good precision 
and accuracy. The results of the proposed method were com-
pared with those of reference method using point and inter-
val hypothesis. It is apparent that the calculated /- and F-val-
ues are less than the theoretical ones at 95% confidence level 
which showed no significant difference between methods 
compared with regard to accuracy and precision. The interval 
hypothesis test has also confirmed that the true bias of all 
samples is <±2% at 95% confidence level. For pharmaceuti-
cal analysis, a bias of ±2% is acceptable and thus the limit of 
acceptance interval is within 0L~O-98 and 0,j=l.O2. 
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